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 Abstract 
Personalised cancer management has the potential to improve prognostic 
modelling and clinical outcomes, and to deliver tailor-made therapies. The aim of this 
study was, firstly, to conduct a systematic review of survival outcomes using a 
combination of HPV and p16 status in oropharyngeal cancers (OPC), with a particular 
focus on the significance of the discordant groups. Secondly, to investigate the drug 
re-purposing prospects of three drug targets (INH001, INH002, INH003) using HPV 
negative (SCC040) and HPV positive (VU147) head and neck cancer cell lines.  
Two independent reviewers performed a systematic review of the literature. In 
total 1318 OPC cases were identified from the 7 included studies. Pooled analysis 
found the HPV+/p16+ group with the best prognostic outcomes, followed by the 
HPV-/p16+ cohort. The worst prognosis outcomes were found with HPV-/p16- 
followed by HPV+/p16-. The 5-year overall survival rates were 81%, 58%, 32% and 
42% respectively.  
The three drug targets were tested using proliferation, migration, flow 
cytometry and clonogenic assays. Both INH001 and INH003 significantly reduced 
proliferation of SCC040 cells at 72 hours compared to untreated control (74% +/-8.9 
and 93% +/-0.4 respectively). Only INH003 significantly reduced proliferation of 
VU147 cells at 72 hours (86% +/-1.7). Similarly both drugs demonstrated a 
significant reduction in SCC040 cell survival using the clonogenic assay (99.5%+/-
0.5 and 83% +/-8.7 respectively). INH003 also exhibited a significant effect on 
SCC040 cells in the flow cytometry cell cycle analysis.  
These results demonstrate the hypothetical value of prognostic studies to 
increase our understanding of cancer pathophysiology and patient outcomes. 
Furthermore there is promise in drug re-purposing methodology to increase the 
availability of novel and effective cancer therapies.  
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1.1 Head and neck cancers 
	
1.1.1 Basic anatomy 
 
The term head and neck cancer (HNC) refers to a heterogeneous group of 
malignancies, arsing from any sub-site within the region but generally excludes brain 
tumours (MedlinePlus, 2014). Anatomical sub-sites include the oral cavity, 
nasopharynx, oropharynx, hypopharynx, thyroid, and larynx (Figure 1.1). Omitting 
thyroid and skin tumours, over 90% of HNC are squamous cell carcinoma (SCC) 
arising from mucous membranes (Suh et al., 2014). Thus they are usually referred to 
as HNSCC (head and neck squamous cell carcinoma).  
 
 
Figure 1.1: Anatomical sub-sites of head and cancers (THANC, 2015) 
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1.1.2 Epidemiology  
 
Worldwide incidence of HNC is estimated to be over 500,000 new cases per 
year (Jemal et al., 2011), with 300,000 related deaths (Boyle et al., 2008). Globally, it 
is the 5th most common cancer (Siegel et al., 2012), and ranked 8th in cancer-related 
deaths (Ragin et al., 2007a). There are considerable variations in incidence depending 
on both anatomical sub-site and geography.  
 
 In England the overall incidence of HNC has increased since 1990, according 
to a recent report (OCIU, 2010). However, the rates and trends between HNC types 
are variable, with considerable geographical differences. Between 1990 and 2006 the 
incidence of oral, oropharyngeal, palate, salivary gland and thyroid cancer has risen. 
The most significant increase has been observed with oropharyngeal cancer, which 
has more than doubled (OCIU, 2010). In contrast the incidence of nasopharyngeal and 
hypopharyngeal cancer has remained constant throughout this period. Laryngeal 
cancer is the only HNC type to have shown a reduced incidence of almost 20%. 
Despite there being common risk factors for all HNC types such as smoking and 
alcohol, there are some risk factors unique to certain subtypes. This may, in part, 
account for the variability in incidence rates.  
 
Mortality rates from HNC have improved within the same period that has seen 
the increase in overall incidence (OCIU, 2010). This improvement in mortality is seen 
across the subtypes, however, oropharyngeal cancer mortality rates appear to have 
increased at a considerably slower rate than incidence. This suggests that while 
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incidence has increased significantly the modest increase in mortality rates may be 
attributed to improved disease management or changes in demographics profiles.    
 
1.1.3 Risk factors 
 
There are various risk factors associated with HNC, with certain sub-types 
related to specific causes. Smoking and alcohol are associated with the majority of 
cases, and both have a synergistic effect (Maier et al., 1992).  The change in incidence 
and mortality rates of HNC are likely to be related to these and other risk factor 
variations.  
 
1.1.3.1 Smoking 
 
In the 1950s several studies were published describing a link between smoking 
tobacco and lung cancers (Doll et al., 1950). Since then the role of smoking in cancer 
pathogenesis has been well established. Smoking is the major risk factor for all HNC 
subtypes (IARC, 2014). One study reported a risk of developing HNC that was 
greater than doubled for ever smokers compared to never smokers in patients that 
were also never drinkers (Hashibe et al., 2007). This association is linked in a dose-
response manner according to quantity, duration and pack years. A large prospective 
study of 476.211 participants demonstrated a difference in HNC risk dependent on 
gender and smoking habits (Freedman et al., 2007a). Incidence rates of HNC for male 
never, previous and current smokers were 24.4, 36.9 and 147.3 per 100,000 person-
years of follow up respectively. Rates for females were 4.8, 17.2 and 75.7 
respectively. However, this study concluded that smoking is likely to influence HNC 
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pathogenesis more significantly in females than males; with smoking attributed to 
approximately 75% HNC cases in the female cohort, compared to 45% in men.  
 
The risk of HNC appears similar among different forms of tobacco smoking, 
such as cigars and pipes. A recent study found patients who had smoked cigars but 
never cigarettes had a HNC odds ratio of 2.54 (Wyss et al., 2013), whereas pipe-
smokers had an odds ratio of 2.08. The anatomical site of HNC can also vary 
according to the method of smoking. For example, reverse smoking (i.e. inserting lit 
end of cigarette into oral cavity) is associated with cancer of the hard palate (Van Der 
Eb et al., 1993).  
 
The role of other smoking products, such as marijuana (cannabis), as risk 
factors in HNC is less clear. The use of marijuana has been associated with an 
increased risk of other cancers, such as lung malignancy (Callaghan et al., 2013). 
However, a case-controlled study conducted for HNC patients appeared to show no 
significant increase in cases, but this could not exclude a moderate effect (Berthiller et 
al., 2009). 
 
1.1.3.2 Chewing products 
 
The use of smokeless tobacco, such as chewing, is highly prevalent among 
South Asians (Abbas et al., 2014), and is a particular risk factor for oral cancer. A 
case-controlled study among a population in New England analysed the association 
between HNC rates and smokeless tobacco use (Zhou et al., 2013). Comparing ever 
users of smokeless tobacco to never cigarette users there was a significant increased 
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risk of cancer (odds ratio = 4.06). Similar to smoking tobacco, the risk was correlated 
to duration of use.  
 
Non-tobacco chewing products related to HNC include betel nut. The betel nut 
seed, also known as areca nut, is derived from the areca fruit (DrugInfo, 2014). The 
seed is used to create betel quids, which is commonly chewed among the Asian 
population. A meta-analysis showed more than double increase in HNC cases in non-
smokers when comparing betel nut users against non-users (Thomas et al., 2007). The 
betel nut is also sometimes combined with tobacco. 
 
1.1.3.3 Alcohol 
 
Alcohol is another major risk factor for HNC, and is dose-dependent. A 
pooled analysis of over 10,000 HNC cases demonstrated a doubling of risk among 
heavy drinkers (>3 drinks/day) who were never smokers (Hashibe et al., 2007). In a 
prospective questionnaire study, which included over 500,000 patients, analysis of 
cancer risk and alcohol consumption was performed (Freedman et al., 2007b). An 
interesting observation was that never drinkers had an increased incidence rate (per 
100,000 person-years) of HNC (61.3 for males, 20.4 for females) compared to low-
level drinkers (<1 drink/day; 34.4 for males, 14.7 for females). Thus this suggests a 
protective effect of alcohol at low consumption rates. However, among heavy 
drinkers (>3 drinks/day) HNC incidence was 77.6 for males, and 75.3 for females.  
 
The synergistic effects of alcohol and tobacco are thought to be multiplicative 
rather than additive. In a multicentre and worldwide case-controlled study a moderate 
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increase in oral cancer risk was demonstrated in relation to consumption of alcohol or 
smoking alone (Castellsague et al., 2004). However, both alcohol and smoking in 
combination increased the rate of oral cancer 13-fold.  
 
1.1.3.4 Viruses 
 
In recent years substantial evidence has emerged regarding the role of viruses 
in HNC pathogenesis. The most prominent example is human papillomavirus (HPV). 
Historically HPV has been strongly associated with cervical cancers and are classified 
as a sexual transmitted disease (CDC, 2014). In 1976 Professor Harald zur Hausen 
first suggested a link between papillomavirus and cervical cancer, later earning him a 
Nobel Prize in 2008 (zur Hausen, 1976). Infection with HPV is thought to account for 
>99% of cervical cancers, particularly high risk HPV (Walboomers et al., 1999). 
Other cancers related to HPV include oropharyngeal (Figure 1.2). In 1983 Syrjanen et 
al first described the relationship between oral cancer and HPV infection (Syrjanen et 
al., 1983).  
 
 
Figure 1.2: HPV-related cancers (PHE, 2014) 
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 The relationship between HPV infection and risk of HNC is believed to be 
independent of alcohol and smoking history (Hennessey et al., 2009). In particular, it 
is oropharyngeal cancers (OPC) that have shown the most significant association with 
HPV infection. The role of HPV in these cancers will be discussed further (Section 
1.2). HPV can be sub-classified into low and high-risk types. In both cervical and 
HNC the most prevalent HPV type is high-risk HPV16. This common subtype is 
likely transmitted between anatomical sites by sexual practices, such as oral sex. 
Regarding the change in incidence rates of HNC, particularly OPC, this may represent 
a change in sexual habits in the past few decades (Mercer et al., 2013). There is also 
substantial evidence of the prognostic value of HPV infection in HNC (Ragin et al., 
2007a, Dayyani et al., 2010, O'Rorke et al., 2012).  
 
The Epstein-Barr virus (EBV) has been implicated in the pathogenesis of 
nasopharyngeal cancers. EBV belongs to the herpesvirus family, and worldwide the 
majority of the adults are thought to be carriers (Thompson et al., 2004). In 1964 Sir 
Michael Epstein was the first to describe the association between EBV infection and 
cancer (Epstein et al., 1964). Infection with EBV is commonly associated with 
Burkitt’s lymphoma, although not classified as a HNC tumour it can affect head and 
neck sub-sites. EBV is estimated to contribute to approximately 90% of 
nasopharyngeal cancers (Thompson et al., 2004). A retrospective review of HNC 
samples analysed the rate of EBV infection among sub-types of HNC, including 
oropharyngeal tumours (Goldenberg et al., 2004). Only 1% of samples were EBV 
positive, and 23% showed trace EBV DNA. Therefore it appears EBV does not play a 
prominent role in other HNC pathogenesis.  
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1.1.3.5 Environmental factors 
 
There are several occupational and environmental risk factors related to HNC. 
The effect of exposure to wood dust among workers of wood-related industries was 
assessed during a meta-analysis of over 28,000 participants. There was an apparent 
increase in sinonasal and nasopharyngeal cancer rates among those exposed to wood 
dust, with a standardised morality ratio of 3.1 and 2.4 respectively (Demers et al., 
1995). In a retrospective study of Swedish construction workers, asbestos exposure 
doubled the risk of laryngeal cancer (Purdue et al., 2006). Furthermore the relative 
risk for pharyngeal cancer associated to cement dust was 1.9. Formaldehyde, a 
chemical used for industrial and household products, has been implicated in 
increasing risk of HNC. An Italian study analysed the association between 16 
chemicals related to occupational hazards and risk of oral and oropharyngeal cancer. 
Formaldehyde appeared to increase the risk of oral cancers, with an odds ratio 1.8 
(Merletti et al., 1991).  
 
1.1.3.6 Non-preventable factors 
 
Many of the risk factors previously mentioned are considered preventable. 
However, the risk of HNC can correlate in certain demographic subgroups. The risk 
of HNC is 3-fold higher in the male population (Langevin et al., 2011). This increase 
is partly attributed to the higher frequency of risk factors among males, such as 
smoking and drinking. Hormonal factors have been proposed as a potential cause for 
gender difference. Post-menopausal women using hormone replacement therapy were 
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found to have a decreased risk of HNC in one study, with more than a 50% reduction 
compared to controls (Langevin et al., 2011).  
 
The incidence of HNC increases with age, with the majority of cases over 50 
years old (Ridge, 2014). However, incidence rates appear to be increasing in the 
younger population (Golas, 2007), and this is thought to be due to the increasing role 
of HPV infection.  
 
There is also a discrepancy in HNC rates between races, with a higher rate of 
laryngeal cancer among African-Americans (Ridge, 2014). Furthermore, survival 
appears worse among African-Americans (Molina et al., 2008), with a greater 
proportion of HPV negative HNC (Weinberger et al., 2010). Variations in risk factor 
exposure may account for these differences.  
 
Genetic factors also contribute to increased risk of HNC. A meta-analysis 
demonstrated an increased risk of cancer among patients with a first-degree relative of 
HNC, with an odds ratio 1.7 (Negri et al., 2009). The risk appeared greater when the 
relative was a siblings rather than a parent. Several genetically related syndromes 
have increased incidence of HNC, such as Fanconi anaemia (Baez, 2008).  
 
1.1.3.7 Other risk factors  
 
Other potential factors can contribute to increasing HNC risk, such as 
variations in diet. A large meta-analysis performed by the INHANCE (International 
Head And Neck Cancer Epidemiology) consortium demonstrated an increased risk of 
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HNC relating to consumption of red and processed meats (Chuang et al., 2012). An 
improved survival was seen among cases with high intake of fruit and vegetables. 
There is also an association between nasopharyngeal cancer and consumption of 
salted fish, with a Chinese study showing the risk more than doubled (Jia et al., 2010).  
 
Immunosuppression can increase susceptibility to various cancers, including 
HNC. Organ transplant recipients receiving immunosuppressants have shown an 
increased risk of HNC. For example, in a recent meta-analysis of liver transplant 
recipients there was a 3.84 increase incidence of HNC (Liu et al., 2014). 
 
1.2 Oropharyngeal cancer 
 
1.2.1 Anatomy 
 
The oropharynx is a three-dimensional structure defined by the anterior 
tonsillar pillar, circumvallate papillae, posterior pharyngeal wall, hard palate and the 
hyoid bone. The region is sub-divided into tonsils, base of tongue, soft palate, 
posterior and lateral pharyngeal walls (Figure 1.3). 
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Figure 1.3: Illustration of oropharynx sub-sites (Lynch, 2006)  
 
 
 
 
1.2.2 Demographics and Trends 
 
Oropharyngeal cancer (OPC) has, and continues to show, a significantly 
increasing incidence. A comprehensive retrospective study was published in 2013 
reporting on the incidence rate of OPC among 23 countries, from 1983 to 2002 
(Chaturvedi et al., 2013). In total almost 70,000 cases of OPC were included in the 
analysis, the majority being male (54,700). The increasing incidence observed was 
mainly seen in developed countries such as USA, France, UK and Japan. In contrast 
there appeared to be non-significant or declining incidence in oral cancers among men 
in these countries, but an increase among women. Changing geographical and gender 
smoking practices is likely to account for the varying incidence rates, particularly in 
westernised societies, where the rate of smoking has decreased in recent years 
(Masironi et al., 1988).  
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As previously described, this global trend is also reflected in England. Here 
the incidence of OPC has more than doubled, from 1 in 100,000 to 2.25 in 100,000 
population in the past few decades (Figure 1.4) (OCIU, 2010). This increase 
represents the most significant rise in any HNC type. A similar rise in OPC incidence 
has been evident in Scotland. Between 1989 and 1996 OPC incidence rate among 
males increased from 18 to 23.6 per 100,000, and 7.3 to 8.5 per 100,000 in females 
(Robinson et al., 2003). In other developed countries this pattern is similarly 
observed. In a Swedish study the incidence rate of tonsillar cancer from 1960 was 
examined, and observed a 2.6% increase per year in males and 1.1% increase in 
females (Hammarstedt et al., 2007).  
 
 
 
Figure 1.4: Illustration of increasing OPC incidence in England (OCIU, 2010) 
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 Several studies have demonstrated that there is a particular increase in OPC 
cases among the younger population. Trends in OPC rates between 1992 and 2007 
were examined in a Canadian study (Johnson-Obaseki et al., 2012). The median age 
of diagnosis of OPC decreased by 0.23 years/year over the study period, while other 
HNC types had an increasing median age. In addition, there was an improved survival 
rate for OPC of 1.5% per year in males. In a US study researchers found an increased 
incidence of tongue and tonsillar cancer between 1973 and 2001 among adults aged 
20-44 years old (Shiboski et al., 2005).  
 
 Logically the length of exposure to traditional risk factors such as alcohol and 
smoking are reduced in the younger population, and therefore less likely to influence 
disease pathophysiology and incidence patterns. Instead trends in incidence appear to 
be related to the increasing role of HPV in the pathophysiology of OPC. The majority 
of HPV positive HNC tend to occur in the oropharynx. In a systematic review of 60 
studies by Kreimer et al. there was an overall HPV prevalence of 25.9% in HNSCC 
(Kreimer et al., 2005). The greatest proportion of HPV positive cases was observed 
among the oropharyngeal cohort (35.6%), with HPV16 the most common subtype 
(86.7%). In a prospective study of 253 HNSCC there was a strong association of HPV 
positive tumours and oropharyngeal site, with an odds ratio 6.2 (Gillison et al., 2000). 
Prevalence rates appear to vary between studies, and are dependent on sub-sites of the 
oropharynx, particularly the tonsils and base of tongue. Analysis of 474 patients in a 
Swedish study demonstrated 79% prevalence of HPV in tonsillar cancers, and 75% in 
base of tongue tumours (Attner, 2013). Further evidence for HPV positive HNSCC 
appearing to be driven via a different pathophysiology comes from their association 
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with patients that have low alcohol exposure, are non-smokers and have wild-type 
p53 gene expression (Gillison et al., 2000).  
 
 The prevalence of HPV in oropharyngeal cancers is thought to be attributable 
to changes in sexual practices and risk factor profile, and this might explain the 
typical demographics described. In one study the risk factors for high risk HPV 
among oropharyngeal cases included age<55 years, higher number of sexual partners, 
oral-genital sex and oral-anal sex (Smith et al., 2004). Furthermore there is evidence 
that early sexual contact increases risk of OPC (Heck et al., 2010).  
 
1.2.3 HPV pathophysiology 
 
1.2.3.1 Structure  
 
1n 1907 an Italian doctor was the first to demonstrate the viral origin of 
common warts (Javier et al., 2008), subsequently found to be caused by human 
papillomavirus. The papillomavirus belongs to the Papovirdae family of viruses, 
which also include the polymaviruses. The HPV virion is composed of an icosahedral 
structure measuring 55nm, and having no envelope (Fields et al., 1996). The virus is 
formed as a 8kb double-stranded DNA circular structure, contained within a protein 
capsid. Various viral genes are encoded within the genome, and subdivided as early 
and late (Figure 1.5). The virus infects only epidermal cells, in either skin or mucosal 
layers. 
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Figure 1.5: HPV16 genome structure  
 
1.2.3.2 Classification 
 
There are over 120 HPV types, which are classified into cutaneous and 
mucosal (Fernandes et al., 2013). Approximately 40 types are associated with 
mucosal infection. The HPV types are further classified as low or high risk, 
depending on their benign or malignant potential. Low-risk HPV include HPV-6 and 
HPV-11, and are associated with benign genital warts and laryngeal papillomatosis. 
The high-risk HPV, such as HPV-16 and 18, are associated with various cancers, in 
particular cervical cancer. The most common type among oropharyngeal cancer is 
HPV-16 (Kreimer et al., 2005).  
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1.2.3.3 Pathogenesis 
 
In order to infect epithelial cells the HPV virus must first enter the basal cell 
layer, which is likely achieved via small breaks in the skin or mucosa (Figure 1.6). 
The basal layer contains replicating stem cells that are essential for viral maintenance. 
The virus then enters an incubation period that can last weeks, months or years 
(Fernandes et al., 2013). Replication of the virus is considered in two stages (Munoz 
et al., 2006). First, the viral particles are maintained at a low count within the basal 
cell layer, thus evading the host immunity. The early viral proteins E1 and E2 
contribute to the initial maintenance phase. During the life cycle of the epithelial layer 
the basal cells migrate towards the suprabasal layer and undergo terminal 
differentiation, with the virus entering the second stage of replication. Viral copy 
numbers increase dramatically in stage two, multiplying to thousands of viral copies 
per cell. The E4 and E5 viral proteins support replication and promote maturation of 
the virus.  
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Figure 1.6: Life cycle of HPV- 1) HPV gains access to basal stem cells through areas 
of micro-trauma in the epithelial cell layer, 2) Entry into basal cells via endocytosis, 
3) Maintenance phase with low viral replication, 4) Differentiation-dependent phase 
with high viral replication, 5) Complete HPV particles are released during normal 
epithelial desquamation  
 
The key oncoproteins in HPV pathogenesis are E6 and E7, working together 
to immortalise keratinocytes (Figure 1.7). E6 binds and inactivates p53, thus 
inhibiting apoptosis. Wild-type p53 acts as a tumour suppressor gene and is activated 
by DNA damage. The p53 functions include modulation of cell cycle and senescence 
(Scheffner et al., 1990). The E6 oncoprotein also induces telomerase activity by 
activating the hTERT promoter (Liu et al., 2009). E7 binds and promotes degradation 
of pRb (retinoblastoma protein), which is also a tumour suppressor gene. Normal pRb 
functions to block cell cycle progression from G1 to S-phase by binding to E2F factor 
(Giacinti et al., 2006). However, disruption of pRb by E7 promotes unregulated entry 
of cells into S-phase, with E7 also interacting directly with E2F transcription factor 
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(Fernandes et al., 2013). Cells entering unregulated S-phase tend to promote apoptosis 
via the p53 pathway. However, the E6 inactivation of p53 prevents apoptosis and 
allows abnormal cells to persist. The process of cell immortalisation accumulates 
abnormal mutations and chromosomal instability, and eventually can lead to cancer 
formation. The late genes L1 and L2 code for the viral capsid. Once the virus has 
matured and assembled they are released during the normal desquamation of 
epithelial cells. The life cycle of the virus ensures there is little interaction with the 
host immunity. Eventually most infected individuals clear the papillomavirus, but 
persistence can vary according to the HPV type (Bulkmans et al., 2007).  
 
 
Figure 1.7: Illustration of HPV E6 and E7 interactions with host cell pathways 
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1.2.3.4 Diagnosis 
 
Detection of HPV in oropharyngeal cancer can be performed by either direct 
or indirect methods. Direct methods include polymerase chain reaction (PCR), in-situ 
hybridisation (ISH), antibody detection and Southern blot assay (Venuti et al., 2012). 
The most common techniques are PCR and ISH. The most common indirect method 
is detection of p16 by immunohistochemistry (IHC).  
 
The PCR method of detection also includes reverse transcriptase PCR (RT-
PCR). These methods are highly sensitive for HPV detection, but have several 
limitations. PCR techniques can be time and resource consuming. They also have 
reduced specificity, and are unable to distinguish between episomal and integrated 
HPV. However, emerging new PCR techniques have shown improved specificity to 
be able to detect HPV active disease.  
 
In contrast to PCR the ISH method of HPV detection is highly specific, but is 
limited by low sensitivity. While PCR requires a very low number of viral DNA for 
detection, positivity with ISH is estimated to require at least 10 viral copies per cell 
(Venuti et al., 2012).  
 
Numerous studies have included p16 IHC as an indirect detection method of 
HPV-related tumours. This method utilises monoclonal antibodies against p16ink4a, 
with positivity calculated according to staining patterns. However, there are several 
definitions for positive staining, which include various percentages (e.g. ≥70%) of 
p16 staining within the tumour sample. This technique is also dependent on the 
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observer. Previous studies have suggested algorithms for accurate detection of HPV 
infection in HNSCC samples, combining p16 IHC with direct HPV detection methods 
(Smeets et al., 2007).   
 
Several studies have demonstrated a strong correlation between HPV status 
and p16 expression. In a study by Ang et al. 93% of HPV positive OPC cases were 
p16 positive; defining p16 positivity as ≥70% strong and diffuse nuclear and 
cytoplasmic staining (Ang et al., 2010). In contrast the HPV negative OPC cohort 
were positive for p16 in 18.8%. In a prospective study comparing HPV ISH and p16 
IHC detection methods the authors discovered 100% of HPV-16 HNSCC tumours 
were positive for p16, using the ≥70% cut-off point (Singhi et al., 2010). There were 
also 24% HPV negative cases showing p16 positivity. A recent meta-analysis in 2014 
investigated the correlation of HPV and p16 overexpression among oropharyngeal 
cancer cases, with a total of 39 studies included (Gronhoj Larsen et al., 2014). The 
studies differed according to HPV (PCR and/or ISH) and p16 detection methods, 
including various p16 staining cut-off points. The reviewers compared the sensitivity 
of p16 correlation to HPV status according to three p16 cut-off points; ≥70%, 5-70% 
and verbal definition only. The highest correlation of p16 to HPV appeared within the 
studies using ≥70% cut-off, with a combined sensitivity of 0.927. Studies with 5-70% 
cut-off had a sensitivity of 0.894, and verbal only was 0.791. 
 
1.2.3.5 The role of p16 
 
The p16 gene (INK4A) was first discovered as a cyclin-dependent kinase 
(CDK) inhibitor in 1993 (Serrano et al., 1993). The gene is located on chromosome 
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9p21 and codes for a 16kDa protein product.  The CDK family are important factors 
in normal cell cycle control. Therefore, considerable research has focused on CDK 
inhibitors, such as p16.  
 
p16 protein functions to prevent G1 to S-phase transition within the cell cycle 
via interaction with the pRb pathway (Romagosa et al., 2011). Initially p16 binds to 
CDK4 or 6, thereby preventing the formation of cyclin D-CDK4/6 complex (Figure 
1.8). This complex normally functions to phosphorylate pRb factors. The resultant 
hypo-phosphorylated Rb protein continues to bind and inactivate E2F transcription 
factor. E2F transcription factor regulates genes involved in DNA replication, and 
therefore inhibition by hypo-phosphorylated pRb leads to cell cycle arrest and 
proliferation.  
 
 
Figure 1.8: p16-pRb pathway and cellular interactions (Bennett, 2003)  
 
The pathophysiological mechanism of HPV-induced cancers appears to occur 
via disruption to the p16-pRb pathway. While E7 expression inactivates pRb function, 
there is an effect on the regulation of p16 by disruption of the normal negative 
regulation by functional pRb (Hara et al., 1996). Therefore, one expects an 
overexpression of p16 in HPV positive cancers (Figure 1.7). Furthermore, 
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overexpression of p16 can vary by cellular location between nuclear and cytoplasmic. 
The role of p16 within the cytoplasm is not clearly understood (Romagosa et al., 
2011).  
 
The importance of p16 in cancer pathogenesis is demonstrated by the 
frequency of deletions, mutations and methylation of p16 among several 
malignancies. Within head and neck cancers there is a reported average of 50% 
homozygous deletions, 10% mutations and 20% methylation of the p16 gene (Liggett 
et al., 1998).  
 
1.2.4 Prognostic biomarkers 
 
The World Health Organisation (WHO) defines a biomarker as “any 
substance, structure or process that can be measured in the body or its products and 
influence or predict the incidence of outcome or disease” (WHO, 2011). The use of 
cancer biomarkers is well illustrated with one of the most well established being 
HER2 detection in a proportion of breast cancer cases. Those tumours expressing 
HER2 tend to be more aggressive than HER2 negative disease (Madell, 2014). The 
availability of this biomarker also allows for targeted therapy against those tumours 
expressing HER2, and treatments such as Herceptin have been shown to improve 
survival in HER2 positive breast cancer. Similar biomarkers have been investigated 
for oropharyngeal cancers, particularly HPV and p16 positivity.  
 
 
Chapter 1- Introduction 
 
 24 
1.2.4.1 HPV  
 
There is clear evidence from multiple studies demonstrating improved 
prognosis of HPV positive compared to HPV negative HNSCC. An early study by 
Gillison et al. demonstrated a 40% increased overall survival and 59% improved 
disease-specific survival in HPV positive HNSCC (Gillison et al., 2000). In an 
analysis of 60 primary tonsillar cancers there was an improved 3 and 5-year survival 
rate between HPV positive cases compared to HPV negative (Mellin et al., 2000). The 
3-year survival was estimated at 65.3% and 31.5% respectively, with 5-year survival 
53.5% and 31.5% respectively. A further study on tonsil cancers also reported on 
improved recurrence and survival outcomes in HPV positive tumours (Li et al., 2003). 
 
 Additional studies have reported on survival outcomes in OPC with respect to 
HPV positivity. Researchers investigating the prognostic role of HPV in oral and 
oropharyngeal cancers demonstrated a significantly better overall survival when 
compared to HPV negative cancers (73% vs. 35%), as well as disease-specific 
survival (79% vs. 45%), with HPV the most reliable prognostic marker in OPC 
(Klozar et al., 2008). A retrospective study of OPC cases found a statistically 
significant improvement in overall and disease-free survivals, as well as locoregional 
control, in the HPV positive cohort (Sedaghat et al., 2009). In a US study of cancer 
registries there was a significant difference in median survival between HPV positive 
and negative OPC cases of approximately 131 and 20 months respectively 
(Chaturvedi et al., 2011). 
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 A seminal paper on HPV and survival in oropharyngeal cancer was derived 
from the RTOG-0129 study data by Ang et al, involving a multi-centre research 
collaboration (Ang et al., 2010). The RTOG-0129 study was a randomised-controlled 
phase III trial comparing two regimens of concurrent radiotherapy and chemotherapy 
in advanced HNSCC. Between 2002 and 2005 a total of 743 patients were enrolled 
into the trial, with 60.1% (433) oropharyngeal cancer cases. The HPV status was 
determined for 323 OPC cases, with 63.8% testing positive for HPV by ISH. The 
overwhelming majority of HPV positive OPC tested positive for HPV-16 (96.1%). 
Investigation of survival outcomes using Kaplan-Meier analysis revealed 3-year 
overall survival in HPV positive OPC was 82.4%, with HPV negative at 57.1%. 
Similarly the rates for progression-free survival were 73.7% and 43.3% respectively. 
Multivariate analysis, adjusting for various confounders, estimated a 58% reduction in 
risk of death in the HPV positive cohort. The researchers then performed recursive-
partitioning analysis and found HPV status to be the most significant determinant of 
survival, followed by number of pack-years smoking, nodal stage (HPV positive only) 
and tumour stage (HPV negative only). They used these 4 factors to divide 
oropharyngeal cancer cases into three separate risk groups; low, intermediate and 
high. The 3-year overall survival rates in these groups were 93%, 70.8% and 46.2% 
respectively (Figure 1.9). This example of risk stratification offers a potential use in 
both the research and clinical setting.   
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Figure 1.9: Kaplan-Meier curves and 95% confidence intervals according to risk 
stratification of oropharyngeal cancer cases (Ang et al., 2010) 
 
 In recent years there have been several systematic reviews and meta-analyses 
assessing the prognostic value of HPV in HNSCC. An early review by Ragin et al. 
included 37 studies, with patient number per study ranging from 22 to 254 (Ragin et 
al., 2007b). Twelve studies contained site-specific data. Analysis of all HPV positive 
HNSCC cases demonstrated an overall improvement in survival of 15% compared to 
HPV negative cases. This effect was even greater in a subset analysis of 
oropharyngeal cancer cases, with an improvement in disease-free survival of 49%, 
and overall reduction in risk of death of 28% in HPV positive patients.. A further 
review published in 2010 included a total of 5681 HNSCC cases from 34 studies, with 
an overall HPV prevalence of 22% (Dayyani et al., 2010). Meta-analysis showed an 
improved survival of 59% in HPV positive HNSCC, and sub-group analysis of 
oropharyngeal cases was 60%. A more recent review by O’Rorke et al. examined a 
total of 42 studies (O'Rorke et al., 2012). Improved overall survival (54%) in HPV 
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positive HNSCC was demonstrated by meta-analysis. Pooled hazard ratios for 
oropharyngeal cancers indicated a 53% reduction in risk of death. This effect size was 
later confirmed in another meta-analysis of prognostic markers in OPC, which 
included 18 studies related to HPV.  An improvement in overall survival of 57% was 
seen in HPV positive cases (Rainsbury et al., 2013).  
 
1.2.4.2 p16  
 
As described, the pathophysiological mechanism of HPV infection indirectly 
interacts with p16 expression via inactivation of pRb (Section 1.2.3.2). Correlation of 
HPV status and p16 appears highly sensitive. Therefore p16 testing has been 
suggested a surrogate marker of HPV-related oropharyngeal cancers (El-Naggar et al., 
2012, Langendijk et al., 2010).  
 
The detection of p16 in oropharyngeal cancers has also shown prognostic 
ability. One study investigated the prognostic significance of p16 in 123 
oropharyngeal SCC, and found improved survival parameters (Weinberger et al., 
2004). Compared to patients with normal p16 expression, those with over expression 
(>80% tumour staining) had an 83% reduced risk of local recurrence, along with 
improved disease-free survival (64%) and improved overall survival (58%). Over 
expression of p16 remained an independent prognostic indicator in multivariate 
analysis. In a more recent study of 102 OPC the 5-year survival rate for p16 positive 
(≥5% tumour staining) cases was 59.3%, compared to 24.5% in the p16 negative 
cohort (Fischer et al., 2010). The tumour status of p16 appeared to be the strongest 
prognostic marker in multivariate analysis. Within the RTOG-0129 study (Ang et al., 
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2010) p16 status was used to stratify cases. The authors reported 3-year overall 
survival of 83.6% in the p16 positive group and 51.3% in p16 negative group, and 3-
year progression-free survival rates of 74.4% and 38.4% respectively. Adjusted p16 
hazard ratio of death was 0.33. The meta-analysis by Rainsbury et al. included 6 
studies on p16 and survival, with a pooled relative risk of 0.43 in p16 positive cases 
(p<0.00001). Among the included studies the cut-off for p16 positivity ranged from 
25-70% (NB- 2 studies did not specify cut-off value), but the results remained 
significant after sensitivity analysis.   
 
1.2.4.3 Other oropharyngeal biomarkers 
 
The majority of studies reporting on oropharyngeal cancer and survival have 
utilised detection of HPV DNA and/or p16 staining as diagnostic and prognostic 
biomarkers. There has been increasing interest in antibody detection methods related 
to HPV infection. In a study by Kreimer et al. a cohort of HNSCC were tested for pre-
diagnosis biomarkers of HPV, including 135 OPC cases. HPV-16 E6 antibody was 
detected in 34.8% of OPC pre-diagnosis plasma samples, but only 0.6% in control 
samples (Kreimer et al., 2013). The increase in E6 plasma level was detected more 
than 10 years prior to diagnosis. In a recently published meta-analysis prognostic 
biomarkers were investigated, including HPV, p16, p53 and HIF1α (Rainsbury et al., 
2013). While high-p53 level was correlated with improved overall survival, this was 
not statistically significant. Only HPV and p16 demonstrated statistically significant 
improvement in overall survival. Various other biomarkers were also identified from 
selected studies, but a meta-analysis could not be performed due to the small study 
sizes.  
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A multicentre trial (PredicTr-OPC), co-ordinated by InHANSE (Institute of 
Head and Neck Studies and Education), is currently underway to investigate 
numerous potential prognostic biomarkers in oropharyngeal cancers.  
 
1.2.5 Discordant groups 
 
As demonstrated, a strong improvement in survival is seen in HPV positive 
HNSCC compared to HPV negative, particularly oropharyngeal SCC. Furthermore, 
the majority of HPV positive tumours also show p16 positivity, while HPV negative 
tumours are more likely to show p16 negativity. Both HPV and p16 are independent 
markers of improved prognosis. However, there remain two so-called discordant 
groups where HPV and p16 do not correlate, HPV+/p16- and HPV-/p16+. By 
utilising data from existing studies it is possible to calculate proportion of 
oropharyngeal cancers belonging to four subgroups; HPV+/p16+, HPV-/p16-, 
HPV+/p16- and HPV-/p16+. Several studies examples are included in Table 1.1.  
 
Study 
reference 
HPV+/p16+ HPV-/p16- HPV+/p16- HPV-/p16+ 
(Ang et al., 
2010) 
59% 29% 2% 7% 
(Klussmann et 
al., 2003) 
47% 47% 6% 0% 
(Hafkamp et 
al., 2008) 
40% 53% 1% 6% 
(Abbas et al., 
2014) 
50% 43% 4% 3% 
Table 1.1: Example studies with proportion of oropharyngeal cases per subgroup 
 
These studies demonstrate that while the two discordant groups represent a 
minority of cases, they are not insignificant. There are conflicting reports regarding 
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the prognostic significance of these two groups. A total of 239 oropharyngeal cases 
were analysed in a retrospective study by Lewis et al. (Lewis et al., 2010). The 
authors concluded that there appeared to be no difference in survival rates between 
HPV+/p16+ and HPV-/p16+, and suggested p16 testing alone for risk stratifying 
cases in future. However, Perrone et al. reported results contradicting this (Perrone et 
al., 2011). This study indicated similar reduced overall survival between HPV-/p16- 
and HPV-/p16+. To date no adequate study or systematic review has addressed the 
prognostic significance of these subgroups. This subject will be addressed in this 
thesis. 
 
1.3 Current treatments in Head and Neck cancers 
 
The management of head and neck cancers is dependent on several factors 
including tumour site, histological type, pathological grade and TNM stage. 
Treatment is also dependent on whether the tumour is primary, secondary or recurrent 
disease. Patient-related factors comprise of age at presentation, premorbid status, co-
morbidities and patient’s preferences. The approach to management of these cancers 
will involve a multi-disciplinary team involving surgeons, specialist nurses, 
pathologists, oncologists, radiologists and various allied health professionals.  
 
The aim of treatment is disease control and improved prognosis, while 
preserving the functional ability of involved organs. Numerous modalities and 
regimes exist at present for the management of HNC. The common treatment types 
will be discussed in further detail.   
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1.3.1 Surgery 
 
1.3.1.1 Primary tumour 
 
The intention of surgery is to preserve organ function while ensuring complete 
removal of the tumour with a clear histopathological margin. Depending on factors 
such as site and size of the tumour, several techniques may be employed. These 
include tonsillectomy, pharyngectomy, laryngectomy and tracheostomy. Surgical 
techniques can involve open, endoscopic, robotic and laser surgery. Reconstructive 
surgery maybe required if extensive excision is undertaken in order to preserve or 
regain function.    
 
Locoregional tumour control can be can also be achieved by radical 
radiotherapy. The Scottish Intercollegiate Guidelines Network (SIGN) recommends 
non-surgical treatment if survival rates are similar between both modalities (SIGN, 
2006). In a randomised controlled trial comparing surgery and adjuvant radiotherapy 
with concurrent chemoradiotherapy in 119 HNSCC cases (stage III/VI non-metastatic 
disease) no significant difference in disease-free survival rates between treatment 
arms was detected (Soo et al., 2005). Surgical outcomes can depend on the ability to 
achieve clear margin. In a retrospective cohort study 261 HNSCC patients were 
treated with primary surgery, with 89% demonstrating negative surgical margins 
(Haque et al., 2006). There was almost a 3-fold increase in all-cause mortality in cases 
with positive margins compared to negative. Cases with positive margins were more 
likely to present as advance disease (stage IV), and with a larger tumour size (>2cm).  
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In cases of locoregional recurrence surgery most often offers the best chance 
of salvage, if technically possible. Decisions regarding salvage operations depend on 
previous treatments and likely benefits to patient, along with patient choice, with 
improving survival the primary goal. A meta-analysis of 32 studies estimated an 
overall 5-year survival of 39% in HNSCC cases treated with salvage surgery 
(Goodwin, 2000).  
 
Palliative surgery can be employed in advanced HNSCC or cases unsuitable 
for primary treatment modalities. The aim is to improve symptom control, and can 
involve debulking procedures and tumour embolisation.  
 
1.3.1.2 Neck surgery  
 
A large proportion of HNSCC will have locoregional metastases to cervical 
lymph nodes at presentations. Surgical removal of these involved nodes via neck 
dissection procedures can be utilised. Historically, radical neck dissection (RND) was 
first established and involves removal of ipsilateral cervical lymph nodes from level I 
to V (Subramanian et al., 2006). Non-lymphatic structures are also excised in RND, 
which include sternocleidomastoid muscle, internal jugular vein and spinal accessory 
nerve. Extended neck dissection involves RND with additional removal of lymph 
nodes and/or non-lymphatic structures. However, in modified (functional) radical 
neck dissection there is preservation of one or more of the non-lymphatic structures. 
More recently, a change in the nomenclature and approach to removal of nodal 
disease has led to increasing use of  more selective neck dissection procedures. The 
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principle is to excise certain lymph node groups according to predicted patterns of 
metastasis, dependent on primary tumour site.   
 
HNSCC can present with no apparent neck involvement, clinically or 
radiologically. However, risk of occult lymph node disease can vary between sub-
sites. For example, oropharyngeal SCC has a reported >50% risk of pathological 
occult nodal metastasis in node negative disease (clinically and radiologically), 
compared to <15% in glottic disease (SIGN, 2006). The SIGN guideline recommends 
prophylactic neck treatment in node negative disease if the risk of occult nodal 
metastasis is >20%, with either neck dissection or radiotherapy.  
 
1.3.1.3 Side effects and complications 
 
Surgical treatment is likely to affect functional ability of various head and 
neck organs, and is of course dependent on the type of surgery performed. Generally 
speech, breathing and swallowing can be temporarily or permanently affected. Post-
operative management can be challenging and may require a multidisciplinary input. 
The burden of disease involves physical and mental factors, which must be addressed 
to ensure optimal disease outcomes. 
 
Complications associated with surgery can be defined as general or specific, 
immediate or early or late. Every operation is related to specific complications and 
can include nerve injury, vascular injury or flap-related difficulties. For example, 
pharyngocutaneous fistula (PCF) can occur following a total laryngectomy. In one 
study 246 consecutive patients undergoing total laryngectomy were investigated, with 
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16% developing post-operative PCF (Redaelli de Zinis et al., 1999). Risk factors for 
PCF formation include postoperative haemoglobin <12.5g/dl and preoperative 
radiotherapy (Paydarfar et al., 2006). 
 
1.3.2 Radiotherapy 
 
1.3.2.1 External beam radiotherapy 
 
Radiotherapy (RT) utilises high-energy ionising radiation to treat primary or 
nodal disease. The use of RT can be used as a single treatment modality for curative 
intent (radical RT) in early disease. Alternatively RT can be combined with surgery 
(adjuvant RT) or chemotherapy (chemoradiotherapy), or as palliative treatment 
(palliative RT). Delivery of radiotherapy can be achieved using various regimes 
involving fractionated treatment. Conventional fractionation involves delivery of 1.8-
2Gy daily doses for 5 days per week, over a 6-week period.  
 
Modified (altered) fractionation comprises of variations in daily radiation dose 
or number of fractions as either hypo, hyper or accelerated fractionation. 
Hypofractionation is an increased daily radiation dose delivered over a shorter period 
of time. Hyperfractionation therapy increases the number of dose fractions, while 
accelerated radiotherapy delivers a greater rate of radiotherapy over a shorter period. 
The purpose of the different strategies is to achieve a compromise between disease 
control and treatment toxicity. Numerous studies relating to these radiotherapy 
regimes have been published, and appear inconclusive. A study comparing 
conventional, hyperfractionated and accelerated therapy in HNSCC concluded there 
Chapter 1- Introduction 
 
 35 
was no significant difference in disease response or survival between these treatments 
(Krstevska et al., 2006). Likewise the RTOG study found similar survival rates 
between the accelerated and conventional treatment cohorts, both combined with 
chemotherapy (Ang et al., 2010). However, a meta-analysis of 15 trials appeared to 
show altered fractionation improved overall survival by 8% compared to conventional 
radiotherapy (Bourhis et al., 2006).  
 
Recent advances in radiotherapy include proton therapy and 3D radiotherapy. 
There is increasing interest in a new form of radiotherapy known as Intensity 
Modulated Radiotherapy (IMRT). Using high-precision 3D conformal radiotherapy 
and computer inverse planning allows a greater dose of therapy delivery with reduced 
toxicity to surrounding tissues (Taylor et al., 2004). However, this method can be time 
and resource intensive with unknown long-term results. A recent review by 
O’Sullivan et al. found no significant difference in prognostic outcomes between 2D 
radiotherapy or 3D/IMRT treatment (O'Sullivan et al., 2012). Nonetheless IMRT 
appeared to reduce the rate of xerostomia and osteoradionecrosis in the included 
studies, as well as improve quality of life.  
 
1.3.2.2 Brachytherapy 
 
An alternative to external beam radiotherapy is brachytherapy, which involves 
localised and internal treatment of tumours. This method is reserved for accessible 
tumours, such as oral and oropharyngeal cancers. The theoretical advantage of 
brachytherapy is precise high-intensity radiation delivery with minimal surrounding 
tissue toxicity, with the main disadvantage being lack of access to tumours.  
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1.3.2.3 Side effects 
 
The use of radiotherapy can avoid or minimise the role of surgery, and thus 
maintain functional ability of organs. However, radiation therapy is associated with 
significant early and late side effects that can be debilitating. The severity of these 
complications is dependent on intensity and duration of therapy. Early side effects 
include nausea, vomiting, dysphagia, radiation-induced dermatitis, temporary 
xerostomia and mucositis. In a systematic review of HNSCC treated with 
radiotherapy the average rate of mucositis was 80% (Trotti et al., 2003). Long-term 
complication can include on going dysphagia (sometimes requiring permanent 
gastrostomy feeding), secondary malignancies, osteoradionecrosis and permanent 
xerostomia.  
 
1.3.3 Chemotherapy 
 
1.3.3.1 Current evidence 
 
In the management of head and neck cancers chemotherapy is used in 
combination with radiotherapy, rather than a single modality. Neoadjuvant treatment 
refers to a chemotherapy course prior to definitive surgery or radiotherapy, while 
adjuvant therapy is delivered after such procedures. Concurrent chemotherapy relates 
to combined treatment with radiation. The benefit of chemotherapy in HNC is 
debatable. In a randomised phase III trial comparing locoregional treatment (surgery 
and/or radiotherapy) with or without neoadjuvant chemotherapy in non-metastatic 
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HNSCC, there appeared no significant difference in overall survival between the 
treatment arms (Zorat et al., 2004). However, neoadjuvant therapy only improved 
survival among the inoperable cases. A meta-analysis study was performed to assess 
the effect of additional chemotherapy with locoregional treatment in non-metastatic 
HNSCC (Pignon et al., 2000). Overall survival improved by 4% at 2 and 5 years with 
additional chemotherapy. Furthermore this benefit was a result of improved survival 
in concurrent treatment, with no advantage seen with neoadjuvant or adjuvant 
therapies. Current SIGN guidelines recommend concurrent chemoradiotherapy with 
Cisplatin, rather than radiotherapy alone, in cases with locally advanced non-
metastatic HNSCC (oral, oropharynx, larynx, hypopharynx) when organ preservation 
is intended or the primary tumour is unresectable (SIGN, 2006). Depending on 
tumour site and stage concurrent chemoradiotherapy can also be utilised with or 
without surgical management. Neoadjuvant and adjuvant therapies are not 
recommended in combination with surgery alone.  
 
Multiple chemotherapy agents exist, and can be used in various combinations. 
Cisplatin is the most commonly used chemotherapy drug in head and neck cancers. 
Other agents include Docetaxel, Carboplatin, 5-fluorouracil (5-FU) and Methotrexate.  
Previous and current trials have investigated Cisplatin therapy with additional drugs. 
For example, the TAX 323 and 324 trials investigated the potential benefit of 
neoadjuvant Docetaxel in combination with Cisplatin and 5-FU in the treatment of 
HNSCC. The TAX 323 phase III trial recruited 358 patients with advanced non-
resectable HNSCC, comparing neoadjuvant Cisplatin and 5-FU therapy with or 
without additional Docetaxel, followed by radiotherapy or concurrent chemotherapy 
depending on disease progression (Vermorken et al., 2007). There was significantly 
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improved progression-free and overall survival in the treatment arm containing 
Docetaxel. The TAX 324 phase III trial recruited 501 patients with advanced HNSCC 
that were either non-resectable or candidates for organ preservation therapy. The 
same neoadjuvant treatment arms were used as for TAX 323, but were followed by 
concurrent chemotherapy. Similarly the overall survival rate was significantly 
improved in the Docetaxel treatment arm (Posner et al., 2007).   
 
1.3.3.2 Cisplatin 
 
Cisplatin was first discovered in 1844 by an Italian chemist named Michele 
Peyrone, and thus termed Peyrone’s chloride (Lebwohl et al., 1998). However, it took 
over a century for the anti-proliferative effects of Cisplatin to be observed by Barnett 
Rosenberg. Initial trials showed promising results in testicular and ovarian tumours. 
In the late 1970s the drug was approved in the USA and worldwide for the treatment 
of various tumours, including head and neck cancers.  
 
Figure 1.10: Illustration of Cisplatin molecule (Lebwohl et al., 1998) 
 
 Cisplatin is an inorganic platinum-based compound belonging to the transition 
metal chlorides (Figure 1.10). It acts as an alkylating agent to induce target cell death 
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by several mechanisms. The drug induces oxidative stress by increasing reactive 
oxidative species, which leads to DNA damage. Alkyl groups also attach to DNA 
bases causing fragmentation and also preventing DNA replication. Cross-linking of 
DNA between bases occurs and there is increased mismatching of nucleotides, 
leading to mutations. Various signalling pathways are activated, including p53, 
causing cell cycle arrest. Eventually these mechanisms initiate apoptosis (Dasari et 
al., 2014).  
 
1.3.3.3 Side effects 
 
The vast majority of current chemotherapy agents are non-specific, and thus 
have numerous side effects. Cancer cells are generally more susceptible to treatment 
due to instability and abnormal replicating patterns. However, all cells within the 
body can be affected. Depending on the replication cycle of cells, early and late side 
effects can occur. Early symptoms may include nausea, vomiting, mucositis, end-
organ damage and hair loss. Damage to haemopoietic cells can lead to anaemia, 
thrombocytopenia and neutropenia. Therefore there is an increased risk of infection 
and neutropenic sepsis. Late side effects can include permanent end-organ damage, 
neuropathy, infertility and secondary malignancies.  
 
1.3.4 Targeted molecular therapy  
 
In recent years there has been increasing research and interest in molecular 
targets for treating head and neck cancers. Theoretically such therapies can improve 
disease outcomes with more favourable side effects profile. An example is Cetuximab 
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(Erbitux), which was initially licenced for locally advanced HNSCC in combination 
with radiotherapy. Currently the license has been extended for recurrent or metastatic 
HNSCC in combination with platinum-based chemotherapy (EMA, 2014).   
 
Epidermal growth factor receptors (EGFR) belong to the ErbB family of 
tyrosine kinase receptors, which are involved in cell signalling pathways (Bonner et 
al., 2006). There is evidence that EGFR is over expressed in HNC cells, and therefore 
an ideal target for molecular therapy (Grandis et al., 1993). Cetuximab is a 
monoclonal antibody that specifically binds to EGFR to disrupt the signalling 
pathways, and thus prevent cell division.  
 
In a multinational randomised trial 424 patients with locoregional advanced 
HNSCC were recruited into two treatment arms; either radiotherapy alone or 
concurrent radiotherapy with Cetuximab (Bonner et al., 2006). There was 
significantly improved locoregional control, progression-free survival and overall 
survival in the Cetuximab group. This has led to recommendations from both SIGN 
and NICE for concurrent Cetuximab and radiotherapy use in locally advanced 
HNSCC who are unsuitable for concurrent chemoradiotherapy (SIGN, 2006, NICE, 
2008). In another multicentre phase III randomised trial 442 patients with untreated 
recurrent or metastatic cancer were enrolled (Vermorken et al., 2008). One arm 
received platinum-based chemotherapy with fluorouracil, and the other the same 
treatment with the addition of Cetuximab therapy. The results showed significantly 
improved progression-free and overall survival in the treatment arm containing 
Cetuximab.  
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As with other therapeutic agents, there are associated side effects with 
Cetuximab. These include skin reactions (e.g. rash), mucositis and deranged liver 
function tests (EMA, 2014).  
 
1.3.5 Novel therapies  
 
There is no doubt that advancements in understanding and management of 
head and neck cancer has led to improved survival outcomes. However, improving 
prognosis cannot be wholly attributed to more effective treatment strategies. The 
increasing role of HPV in disease pathogenesis has been proven to demonstrate 
favourable survival, irrespective of treatment modality. Furthermore, changes in 
survival rates have been modest or unchanged in the past 3 decades in developed 
countries. While early stage disease appear to show excellent long-term prognosis, 
advanced or metastatic HNC continue to demonstrate poor survival. Therefore both 
low and high risk HNC present unique challenges. Although long-term survival is of 
paramount importance to patients, this must be balanced with maintaining a 
reasonable quality of life. There is recent interest in de-escalating treatment, with the 
purpose of maintaining treatment outcomes while reducing long-term toxicity. 
Currently there are several de-escalation trials. An example is De-ESCALaTE HPV, 
which is an international randomised phase III trial, being led by Warwick medical 
school. The aim of this study is to compare the outcomes between Cisplatin and 
Cetuximab, both combined with standard radiotherapy in HPV positive oropharyngeal 
cancers.  
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Besides Cetuximab there has been no major drug discovery in head and neck 
cancer treatment since the 1970s, with the advent of chemotherapy. The panacea drug 
of HNC treatment would ideally demonstrate high efficacy with minimal side effects. 
In order to achieve this target researchers and pharmaceutical companies continue to 
explore various avenues for drug discovery. However, traditional drug discovery is a 
time-consuming and expensive process (Figure 1.11). Drug development can take 
anywhere between 10-20 years (average 12 years) from preclinical testing to approval 
(Dickson et al., 2004). The Association of British Pharmaceutical Industry puts an 
estimate average cost of drug development at £1.15 billion (Triggle, 2014). There is 
also a high failure rate, which can occur at any stage during the process, even after 
drug approval. An alternative to this method of drug discovery is drug repurposing, 
which will be discussed in further detail. 
 
 
Figure 1.11: Illustration of drug development timeline (Roses, 2008) 
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1.4 Drug repurposing 
 
1.4.1 Background 
 
Drug repurposing, also known as drug re-positioning, is the process of finding 
new therapeutic uses for existing drugs. The theoretical advantages of this method of 
drug discovery are reduced timescale and expense. While any agent can be a potential 
target for drug repurposing, the costs can be further reduced by utilising off-patent 
medications. Currently there are several commercial drug libraries that can be utilised 
for the purpose of high throughput screening. One such method has been described as 
the SOSA approach (selective optimisation of side activities), by selectively testing 
existing drugs on new targets (Wermuth, 2006). Established agents will have a well-
known side effects profile and proven safety in human models. Similarly, the 
pharmacokinetic and pharmacodynamic properties would also have been elucidated. 
Therefore drug targets identified from such screening could potentially be utilised in 
the clinical setting in a far shorter timescale.  
 
A famous example of drug repurposing is Viagra (Sildenafil). Initially Viagra 
was developed for the treatment of angina. The drug inhibits PDE5 
(phosphodiesterase) and therefore prevents cGMP breakdown (Ghofrani et al., 2006). 
cGMP is involved in various cell-signalling pathways including mediation of smooth 
muscle relaxation, thus leading to vasodilation. However, volunteers of early studies 
reported several side effects, including penile erection. Although angina treatment 
was the initial target of this agent, eventually the drug was repurposed. In 1998 both 
the FDA and European Agency approved Viagra for the treatment of erectile 
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dysfunction. In 2005 it was also approved for the treatment of pulmonary 
hypertension (Ghofrani et al., 2006).  
 
1.4.2 Cancer therapy 
 
There are numerous examples of drug repurposing for cancer treatments. In 
the 1950s Thalidomide was introduced to treat morning sickness in pregnant women 
(Kim et al., 2011). However, over the course of several years devastating tetrogenic 
side effects were observed in the babies of some mothers, leading to a ban in 1961. 
Further studies of Thalidomide have described the mechanism of action, including 
inhibition of angiogenesis. Renewed interest in this drug has led to repurposing of 
Thalidomide in the treatment of leprosy and multiple myeloma (Singhal et al., 1999).  
 
Commonly used drugs have also shown promise in cancer therapy, including 
Aspirin, Simvastatin and Metformin. In a systematic review of prophylactic Aspirin 
use there appeared to be a decrease in cancer-related incidence and mortality of 
several cancer types, particularly colorectal and oesophageal malignancy (Cuzick et 
al., 2015). Despite the relative increased risk of adverse events, such as 
gastrointestinal bleeding, the benefits appear to outweigh the harms. Metformin is 
commonly used in the treatment of non-insulin dependent diabetes. There is growing 
evidence demonstrating a reduced incidence rate of various cancers with Metfomin 
use. One meta-analysis reported a reduced incidence rate of malignancies in diabetics 
treated with Metformin including colorectal, hepatocellular, prostate and breast 
cancers (Noto et al., 2012). Overall cancer incidence risk was reduced by 33%, and 
cancer-related mortality risk by 34%.  
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1.4.3 The AcceleraTED platform 
 
Development of novel therapies in head and neck cancers is the main aim of 
the AcceleraTED project (Accelerated Translation of therapeutic agents and 
Emerging Devices in Head and Neck and Thyroid cancer). Utilisation of different 
drug libraries and robotic high-throughput screening has identified several drug 
targets. As part of this thesis three of these drug targets have been investigated further 
(INH001, INH002, INH003). 
 
1.5 Aims and Objectives 
 
While head and neck cancers are relatively uncommon compared to other 
malignancies there is an increasing incidence rate worldwide, with a significant shift 
in disease pathogenesis. The role of HPV in HNSCC is becoming more prominent, 
particularly in oropharyngeal cancers. Several prognostic indicators and biomarkers 
have been proposed for risk-stratification. Combining these biomarkers can 
potentially improve prognostic predictions and guide management. Furthermore, 
current treatment regimes appear to have almost reached maximum survival benefits. 
There is a constant need for novel therapies that can improve outcomes while 
minimising toxicity. Drug repurposing is a promising method of rapidly increasing 
available treatments, and has not been systematically investigated in head and neck 
cancers.  Ultimately the aim is to improve outcomes by personalised treatments, 
combining prognostic studies and novel therapies.  
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The main objectives of this project are: 
• To perform a systematic review of survival outcomes in subgroups of 
oropharyngeal cancers according to a combination of HPV and p16 
status. In particular the prognosis among discordant groups will be 
analysed, and pooled analysis performed.   
• To investigate 3 drug targets as potential drug repurposing agents in 
head and neck cancer treatments. Differences between HPV positive 
and negative cell lines will also be examined.   
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2.1 Introduction 
 
 The human papillomavirus (HPV) belongs to a group of viruses with over 100 
genotypes (Gearhart, 2014). They have been associated with epithelial tumours, 
particularly high-risk genotypes such as HPV 16 and 18. Cancers linked to HPV 
infection include cervical, vaginal, anal, and oropharyngeal (NCI, 2012).  
 
Head and neck cancer (HNC), including thyroid cancers, are the 5th 
commonest cancer group worldwide (Siegel et al., 2012). Within this group squamous 
cell carcinoma (SCC) accounts for over 90% of cases, excluding thyroid and skin 
tumours (Schiff, 2013). A recent report of HNC incidence in England shows that 
oropharyngeal SCC (OPSCC) rates have more than doubled since 1990, which is 
more than any other HNC sub-site (OCIU, 2010). This is likely to be due to a change 
in sexual behaviour and risk factor characteristics, with an increasing role of HPV in 
disease pathogenesis.  
 
There has been recent interest in the relationship between HPV and HNC, 
particularly with respect to survival and disease-free outcomes. Systematic reviews 
have demonstrated improved survival in HPV positive patients, particularly in 
OPSCC (Ragin et al., 2007b, Dayyani et al., 2010, O'Rorke et al., 2012). Further 
studies of HPV in OPSCC have focused on various prognostic biomarkers, such as 
p16 and p53 (Rainsbury et al., 2013). The p16 gene codes for a tumour suppressor 
protein (INK4A), and has been suggested as a possible surrogate marker of HPV 
infection (Chen et al., 2012, Dayyani et al., 2010). HPV-related oropharyngeal 
tumours appear to show p16 protein overexpression, via mechanisms previously 
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described (Chapter 1). Furthermore, p16 positive HNC show improved survival 
outcome (Rainsbury et al., 2013).  
 
 While HPV and p16 appear to show favourable prognosis independently, the 
prognostic combination of HPV and p16 to predict survival is unclear. A landmark 
study by Ang et al. risk stratified HPV OPSCC into 3 survival groups (low, 
intermediate, high risk), by a combination of HPV status, smoking and tumour staging 
(Ang et al., 2010). The study found that 93.2% of HPV positive cases were p16 
positive, and 80.3% of HPV negative cohort was p16 negative. However, 3.4% were 
HPV+/p16- and 18.8% HPV-/p16+.  These latter two sub-groups represent discordant 
results, with unknown clinical significance.  
 
A literature search, including CRD (Centre for Reviews and Dissemination) 
databases, found no current systematic review reporting survival outcomes according 
to these 4 sub-groups, particularly the significance of the two discordant groups. The 
aim of this systematic review was to determine the prognostic outcomes of OPSCC by 
analysing combinations of HPV and p16. These include the following: 
 
• HPV+/p16+ (i.e. true positives) 
• HPV-/p16- (i.e. true negatives) 
• HPV-/p16+ 
• HPV+/p16- 
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2.2 Materials and Methods 
 
 Training for the systematic review was undertaken using the InHANSE 
guidelines (Mehanna, 2011), and supplemented with other written articles (CRD, 
2009, Chung et al., 2006, Khan et al., 2003, Ressing et al., 2009). Prior to 
commencing the systematic review a protocol was devised, and approved by the 
review supervisors (Professor Hisham Mehanna and Jayne Wilson).  
 
2.2.1 Search strategy  
	
2.2.1.1 Search Terms 
 
 In order to identify appropriate studies search terms were selected as Boolean 
operators, as follows: 
 
‘HPV’ or ‘human papillomavirus’ or ‘papillomavirus’ or ‘p16’ 
 
AND 
 
‘head’ or ‘neck’ or ‘oral’ or ‘buccal’ or ‘mouth’ or ‘tongue’ or ‘oropharyngeal’ or 
‘tonsil’ or ‘palate’ or ‘pharyngeal’ or ‘pharynx’ or ‘hypopharynx’ or ‘larynx’ or 
‘laryngeal’ 
 
AND 
 
‘cancer’ or ‘neoplasm’ or ‘tumour’ or ‘SCC’ or ‘squamous cell carcinoma’ 
 
AND 
 
‘recurrence’ or ‘prognosis’ or ‘mortality’ or ‘survival’ or ‘outcome’ 
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 The main anatomical head and neck sub-sites were included in the search 
terms in order to ensure no potential study was excluded.  
  
2.2.1.2 Identifying studies 
 
Identification of relevant studies was performed, and repeated by a second 
independent reviewer (Nicola Graham, InHANSE). Initial searches were completed 
on 31st January 2014, using OvidSP (Wolters Kluwer Health, NY, USA). This 
included the following databases: 
 
• Ovid Medline (R) In Process and Other Non-Indexed Citations and Ovid Medline 
(R)- 1946 to Present (National Library of Medicine, USA) 
• Embase Classic and Embase- 1947 to Present (Elsevier, AMS, NED) 
 
A further search was completed using the Cochrane Library (The Cochrane 
Collaboration). References from searches were all exported into EndNote X7 software 
(Thomson Reuters, Version X7.0.1). Study duplicates were removed automatically by 
EndNote on exporting, and using the ‘Find Duplicates’ feature of the programme.  
 
 Unpublished studies (i.e. grey areas of literature) were searched using the Web 
of Science databases (Thomson Reuters, USA). These include conference proceedings 
(1990-Present), Science Citation Index (1900-Present), BIOSIS citation index (1969-
2008), and SciELO citation index (1997-Present). The ProQuest database (Ann Arbor, 
MI, USA) was examined for any relevant dissertations or thesis. Finally, relevant 
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conference websites were searched for abstracts, including AHNS (American Head 
and Neck Society) and ASCO (American Society of Clinical Oncology).  
 
Study selection was then commenced (Section 2.2.2), and reference lists of 
included studies searched for any further references. Review articles were also 
searched for relevant references. An updated search of OvidSP was performed on the 
29th December 2014 to identify any recent studies since the initial search.  
 
2.2.2 Study selection  
 
Selection of relevant studies was performed independently by both reviewers. 
A trial of study selection was completed with 10 studies. Any disagreements were 
resolved by discussion, and if not resolved then the study was included into the next 
stage of selection and discussed with the review supervisors.  
 
The following inclusion criteria were chosen for initial study selection: 
 
• Human studies only 
• Head and neck SCC, any site 
• Report prognostic outcomes according to HPV and/or p16 
• All study types (observational and experimental, retrospective and prospective) 
• Any language 
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Titles were searched using the inclusion criteria, and the databases from both 
reviewers were merged. The number of agreed studies was calculated by EndNote, by 
the removal of duplicates.  
 
All included studies were further analysed by assessing the abstracts, and 
using the following inclusion criteria: 
 
• Oropharyngeal sub-sites only (base of tongue, tonsil etc.) 
• Report on prognostic markers according to HPV and p16 in combination  
 
Excluded articles included non-oropharyngeal cancers, reviews, editorials or 
opinions, and insufficient data. Reasons for exclusions were documented. Full papers 
of selected articles were then collated. Papers with no institutional access were 
located by the University of Birmingham library, and direct email contact with 
authors.  
 
2.2.3 Quality assessment 
 
 In order to assess quality of included studies a quality assessment tool was 
adapted from a previous systematic review (Rainsbury et al., 2013). Each paper was 
scored according to 6 domains (Table 2.1), based on potential biases (Hayden et al., 
2006). Studies were scored 0-2, depending on the number of criteria met within each 
domain (0 = none, 1 = partial, 2 = all), with a total of 12 points. Both reviewers 
performed quality assessment independently, and an average score calculated.  
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Domain 
 
1. Study participation 
• Study population described 
• Recruitment described 
• Inclusion and exclusion criteria  
• Adequate participation  
• Baseline population described 
 
 
2. Study attrition 
• Adequate response rate 
• Information about drop outs 
• No important difference between included patients and 
drop outs 
 
 
3. Prognostic factor measure 
• Clear definition of prognostic factors measured 
• Cut-off points included 
• Method of measure accurate and reliable  
• Adequate proportion of study population have complete 
data 
• Method same for all samples 
 
 
4. Outcome measure 
• Clear definition of outcome measured, including period 
of follow up  
• Method of outcome accurate and reliable  
• Method same for all samples 
 
 
5. Confounding measure 
• All important confounders measured 
• Clear definitions of confounders 
• Measure of confounding accurate and reliable 
• Confounders accounted in study design and analysis 
 
 
6. Analysis 
• Sufficient data for analysis 
• Adequate statistical models used  
• No selective reporting of results 
 
Table 2.1: Quality assessment tool 
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2.2.4 Data extraction 
 
 Full papers were reviewed and relevant data extracted. This data was input 
into a pre-defined spreadsheet (Microsoft Excel for Mac 2011 Version 14.0.0),. These 
included the following fields: 
 
• Study details (Author, Title, Language etc.) 
• Quality assessment score 
• DNA extraction method 
• HPV detection (PCR/ISH) 
• p16 detection and cut-off points 
• Patient demographics for each sub-group (age, sex etc.) 
• Oropharyngeal sub-sites 
• TNM staging 
• Treatments 
• Prognostic outcomes (e.g. overall survival) 
 
All data extraction was performed by one reviewer, and validated by the 
second reviewer. Any disagreements were resolved by discussion.  
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2.2.5 Statistics 
 
 Following data extraction the spreadsheet results were examined with both 
reviewers and supervisor. Prior to statistical analysis the data was discussed with a 
biostatistician (Ikhlaaq Ahmed, CRCTU, University of Birmingham) to determine if a 
meta-analysis was appropriate. In case of insufficient data for meta-analysis a 
descriptive analysis would be performed. To statistically measure inter-rater 
reliability, Cohen’s Kappa score was also calculated. 
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2.3 Results 
 
2.3.1 Study selection  
 
2.3.1.1 PRISMA flow diagram 
 
Figure 2.1: PRISMA flow diagram representing the stages of study selection 
 
 The results are presented according to the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) checklist (Liberati et al., 2009). 
The main database searches included Medline, EMBASE and Cochrane library, and 
yielded 3525 studies (Figure 2.1). A further 954 records were identified from grey 
areas of literature searches, as described in section 2.2.1.2. Reference lists of included 
studies were examined, but no other relevant studies were found.  
 
 
 
 
 
3525 records 
identified in main 
database search  
954 records  
identified from 
other sources 
2726 records after 
duplicates excluded 
2726 records  
screened 
2709 records  
excluded (titles and 
abstracts) 
17 full-text articles 
screened 
10 full-text articles 
excluded 
•  9 insufficient data 
•  1 duplicate study 
7 studies included in 
qualitative analysis 
7 studies included  
in quantitative 
 analysis 
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2.3.1.2 Excluded studies  
 
 After the initial searches were completed all duplicates were removed using 
the EndNote software, leaving 2726 potential studies. Both reviewers screened study 
titles independently. The results of the title screening from both reviewers were 
combined and 682 records remained. Studies were excluded if the titles were 
obviously unrelated to the head and neck cancers, and did not focus on HPV and/or 
p16 prognostic indicators. Following screening of titles the abstracts were further 
analysed according to the initial exclusion criteria, and yielded 279 potential studies.  
 
The abstracts underwent a second screening phase to select studies related to 
oropharyngeal cancers only, with 140 studies remaining. At this stage the final 
inclusion criteria was applied, and studies selected if they related to OPSCC and 
prognostic indicators described according to HPV/p16 combination. In total 17 
studies were selected for full paper screening. Reasons for excluding abstracts are 
detailed in Table 2.2.  
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Reasons for Exclusion Number of Studies 
Insufficient data 54 
No HPV data 47 
No p16 data 11 
Abstract only available 4 
Review article 2 
No access to paper* 2 
Irrelevant 
• Cancer stem cell markers and survival   
• Molecular characterisation of HPV-/p16+ OPC 
 
1 
1 
Editorial 1 
Table 2.2: Reasons for excluded abstracts in second abstract screening phase. 
*Unavailable via The University of Birmingham and British Library services 
 
 The 17 full papers were screened and a further 10 studies were excluded, with 
the majority due to insufficient data and one appearing to be a study with duplicate 
data. In total 7 studies were included in the qualitative and quantitative analysis.  
 
2.3.1.3 Inter-rater reliability  
 
 In order to assess degree of agreement between both reviewers Cohen’s Kappa 
testing was applied (Cohen, 1960). This statistical test takes into account agreements 
that could occur by chance alone, and is calculated as follows: 
 
κ = [Pr(a) – Pr(e)] / [1 – Pr(e)] 
 
 The Pr(a) value represents the actual agreement observed, and Pr(e) the 
expected agreement value. The results of the title screening performed by each 
reviewer is summarised in Table 2.3. 
 
 
Chapter 2- Systematic Review and Descriptive Analysis 
 
 60 
 Reviewer 2 (NG) 
Yes  No Total 
Reviewer 1 
(MJ) 
Yes 283 216 499 
No 183 2044 2227 
Total 466 2260 2726 
Table 2.3: Summary of title screening by both reviewers 
 
 Calculating the Kappa value as follows: 
 
Pr(a) = (283+2044) / 2726 = 0.854 
 
Pr(e) = [(466x499/2726) + (2227x2260/2726) / 2726)] = 0.709 
 
∴  κ = (0.854 – 0.709) / 0.291 = 0.498  
 
 A value of 1 represents perfect agreement between two raters, and 0 an 
agreement no better than that expected by chance alone. However, the Kappa value is 
only one such method to represent inter-rater agreement, with various arbitrary 
systems to define its significance, as seen in Table 2.4. According to this scale the 
inter-rater agreement appears to be moderate at the title screening stage. 
 
Kappa value range Significance of agreement 
<0 Poor 
0-0.2 Slight 
0.21-0.4 Fair 
0.41-0.6 Moderate 
0.61-0.8 Substantial 
0.81-1 Almost perfect 
Table 2.4: Significance of Kappa score, adapted from Landis et al (Landis et al., 
1977) 
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  In Table 2.5 the results of abstract screening by both reviewers is 
summarised, and the Kappa value is as follows: 
 
 Reviewer 2 (NG) 
Yes  No Total 
Reviewer 1 
(MJ) 
Yes 214 22 236 
No 43 403 446 
Total 257 425 682 
Table 2.5: Summary of first abstract screening by both reviewers 
 
Pr(a) = (214+403) / 682 = 0.905 
 
Pr(e) = [(257x236/682) + (425x446/682) / 682)] = 0.538 
 
∴  κ = (0.905 – 0.538) / 0.462 = 0.794 
 
 It appears the inter-rater agreement score improved to substantial during the 
abstract screening stage. 
 
2.3.2 Included studies 
 
2.3.2.1 Descriptive summary 
 
 The systematic search yielded 7 full papers included in the qualitative and 
quantitative analysis. These are summarised in Table 2.6. 
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Reference Study type Country Language Total number 
of patients in 
study 
Number included 
in review analysis 
(Evans et al., 
2013) 
Retrospective cohort 
 
Wales English 147 138 
(Hong et al., 
2013) 
Retrospective cohort 
 
Australia English 647 647 
(Junor et al., 
2012) 
Retrospective cohort 
(2 cohorts) 
Scotland English Cohort 1= 118 
Cohort 2= 136 
Cohort 1 = 77 
Cohort 2 = 103 
(Lewis et al., 
2010) 
Retrospective cohort 
 
USA English 239 209 
(Song et al., 
2012) 
Retrospective cohort 
 
South 
Korea 
English 56 47 
(Stephen et al., 
2012) 
Retrospective cohort 
 
USA English 80 20 
(Weinberger et 
al., 2006) 
Retrospective cohort 
 
USA English 107 77 
Table 2.6: Summary of included papers  
 
 The included studies were published in the period from 2006 to 2013. All 
these papers were designed as retrospective cohort studies and written in English. In 
total 42% (3 studies) were conducted in the USA, and 29% (2 studies) in the UK. 
 
 The first study by Evans et al, conducted in South Wales, identified cases of 
oropharyngeal cancer diagnosed between 2001 and 2006 using pathology databases. 
The aims of the authors were to investigate prevalence of HPV in OPC and their link 
to clinical significance. They collected demographic and outcome data by searching 
electronic heath records, patient notes, and direct contact with General Practitioners. 
In each case a fresh frozen paraffin-embedded (FFPE) sample block was retrieved and 
two pathologists confirmed the histological diagnosis of OPC. In total 147 cases of 
OPC were obtained for analysis, which represented 83% of cases diagnosed within 
the study period. However, only 138 FFPE blocks contained sufficient tumour for 
further HPV analysis.  
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 Hong et al identified 647 cases of OPC treated with curative intent, and 
investigated the significance of the discordant groups. Cases were collected from 10 
Australian centres diagnosed in the period of 1979 to 2009. Their inclusion criteria 
were availability of tumour samples and patient-related data and outcomes, which 
were obtained from institutional databases. The number of excluded cases was not 
mentioned.  
 
 The study by Junor et al was conducted in Scotland using population-based 
databases from a regional referral centre. The focus of the paper was the change in 
treatment of OPC between two cohorts. Cohort 1 was derived from a database of OPC 
cases diagnosed from 1999 to 2001, with the preferred treatment surgery +/- 
postoperative radiotherapy or radiotherapy alone, and neck dissection performed prior 
to radiotherapy for N2/3 disease. In Cohort 2, with OPC cases diagnosed from 2003 
to 2005, the treatment of choice was concurrent chemotherapy and radiotherapy, with 
neck dissection performed post-therapy only if a complete response had been 
achieved.   
 
 Lewis et al investigated the significance of p16 status in OPC cases, 
particularly the discordant p16+/HPV- group. In total they identified 239 OPC cases 
from the Washington University databases diagnosed from 1997 to 2008.  
 
 The study by Song et al was the only Asian-based research identified for 
inclusion in this review, and was conducted in South Korea. The authors identified 56 
cases of tonsillar SCC diagnosed from 1994 to 2010, and investigated the prognostic 
significance of HPV status and several biomarkers, including p16.  
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 The research paper by Stephen et al investigated the clinical significance of 
p16 status in various HPV positive and HPV negative head and neck cancers sub 
sites, including the oropharynx. They selected a pilot cohort of 80 HNSCC cases, 
which consisted of 10 HPV positive and 10 HPV negative tumours from 4 sites (oral 
cavity, oropharynx, larynx and hypopharynx). These cases were identified from the 
Henry Ford Health System (Detroit, USA), and diagnosed in the period of 1986 to 
2003. The selection criteria of specific cases were not described.  
 
 Finally, the study conducted by Weinberger et al investigated the clinical 
significance of p16 expression in OPC. The authors identified 107 patients from the 
Yale-New Haven Hospital database, treated between 1980 and 1999 with primary 
radiotherapy or surgery and postoperative radiotherapy. They excluded cases of 
metastatic disease or incomplete therapy.  
 
2.3.2.2 HPV and p16 testing 
 
 
Figure 2.2: HPV testing methods in the included studies 
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 The results in Figure 2.2 demonstrate the majority of the included studies 
utilised PCR to detect HPV in the tumours. One study (Song et al) used ISH only, 
while 2 studies (Evans et al and Lewis et al) used both methods. The PCR kits and 
controls used varied between the studies. However, all the studies that utilised ISH for 
HPV detection used the Inform HPV III Family 16 probe.  
 
 The prevalence of HPV in the included studies ranged from 36-68%, and is 
summarised in Table 2.7. The average HPV prevalence was 54%. Interestingly the 
lowest prevalence was found in the South Korean study. The majority of HPV 
positive cases among the studies were HPV 16 genotype, with an average prevalence 
of 95%.  
 
Study 
 
HPV Prevalence HPV 16 Prevalence 
Evans et al 50% 97% 
Hong et al 57% 95% 
Junor et al 
 
Cohort 1 = 41% 
Cohort 2 = 63% 
92% (combined) 
Lewis et al 68% * 
Song et al 36% * 
Stephen et al N/A  N/A 
Weinberger et al 61% * 
 
Average prevalence  
 
54% 
 
95% 
Table 2.7: HPV and HPV16 prevalence between studies. N/A- Stephen et al paper 
used a selective pilot cohort, not representative of true HPV prevalence. *Data not 
provided 
 
 Testing of p16 expression involved immunohistochemistry assays, with the 
included studies using either the CINtec Histology kit or DAKO EnVision Flex+ 
system. The percentage staining used to define p16 positivity varied amongst the 
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research papers (Figure 2.3). However, all the included studies defined positivity as 
diffuse nuclear and cytoplasmic staining.  
 
 The variations in both HPV and p16 testing, including cut-off points, do 
introduce a significant bias to these results and must be considered when assessing the 
outcomes of this review.  
 
  
Figure 2.3: The number of studies utilising various p16 staining and percentage 
patterns. N+C- Nuclear and Cytoplasmic 
 
2.3.2.3 Quality assessment scores 
 
 Both reviewers independently scored the included papers according to the 
criteria detailed in Section 2.2.3. These are summarised in Table 2.8. The individual 
scores in each category are detailed in the Appendix. The quality scores for reviewer 
1 (MJ) ranged from 4 to 10, with a mean score of 7.5 (out of 12). Reviewer 2 (NG) 
assigned scores from 5 to 12, with a mean score 7.75.  
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Study 
 
Reviewer 1 (MJ) 
Total score 
Reviewer 2 (NG) 
Total score  
Average Total 
score  
Evans et al 10 12 11 
Hong et al 9 8 8.5 
Junor et al 8 9 8.5 
Lewis et al 7 7 7 
Song et al 4 5 4.5 
Stephen et al 4 5 4.5 
Weinberger et al 8 7 7.5 
 
Overall average 
 
7.25 
 
7.75 
 
7.5 
Table 2.8: Quality assessment scores (total out of 12) given by both reviewers for 
each study 
 
2.3.3 Pooled study demographics 
 
 The demographics from each study were extracted from the selected papers 
and pooled according to the sub-groups of HPV/p16 status. These will be discussed in 
further detail in the descriptive analysis.  
 
2.3.3.1 Sub-group characteristics  
 
 The total number of subjects in each sub-group, sex distribution and average 
of the mean age are summarised in Table 2.9. The majority of subjects (80%) 
appeared in the HPV-/p16- and HPV+/p16+ groups, with the discordant groups 
accounting for a minority of cases (20%). This trend is similar to the collated results 
seen in Table 1.1. All the sub-groups had a higher proportion of male patients, as seen 
in previous literature (Section 1.1.3.6). The sex ratio between the HPV-/p16- and 
HPV+/p16- were similar, approximately 3:1. In comparison the HPV+/p16+ and 
HPV-/p16+ both had a higher proportion of male subjects, approximately 4:1 and 9:1 
respectively.  
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 By collating the mean ages described in each study, an average value was 
derived in order to compare between the sub-groups. As with the sex distribution, it 
appears that the HPV-/p16- and HPV+/p16- groups have comparable values of 61 and 
60.4 years respectively, with similar mean age ranges. The two other sub-groups, 
HPV+/p16+ and HPV-/p16+, had a lower average mean age of 55.3 and 52.2 years 
respectively.  
 
Sub-group Total number 
of subjects 
(%) 
Male (%) Female (%) Average of 
mean age in 
years (range) 
HPV-/p16- 471 (35%) 336 (75%) 114 (25%) 61 (57-66.1) 
HPV+/p16- 194 (15%) 131 (71%) 54 (29%) 60.4 (57-63.3) 
HPV+/p16+ 604 (45%) 478 (82%) 102 (18%) 55.3 (54.5-55.7) 
HPV-/p16+ 61 (5%) 36 (92%) 3 (8%) 52.2 (48.4-55.7) 
Table 2.9: Summary characteristics of the HPV/p16 sub-groups  
 
2.3.3.2 Smoking history 
 
Figure 2.4: Smoking status within each HPV/p16 sub-group. Data collated from 
Evans et al, Hong et al, Junor et al, Lewis et al, and Weinberger et al 
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 All the studies, apart from Song et al and Stephen et al, provided data on 
smoking status. In Figure 2.4 the smoking status between the sub-groups are 
compared. Both the HPV-/p16- and HPV-/p16+ groups were associated with the 
highest proportion of current/previous smoking history, approximately 80%. The 
HPV-/p16- group also had the lowest percentage (3%) of non-smokers. The 
HPV+/p16- group had 71% subjects with a history of smoking. In comparison, the 
HPV+/p16+ group had the lowest proportion (60%) of subjects with a positive 
smoking history, and the highest percentage of non-smokers (24%). 
 
2.3.3.3 Drinking status 
 
 The drinking status of each sub-group was only adequately described in the 
study by Junor et al, and is summarised in Figure 2.5. This study provided 2 separate 
cohorts, and the results have been combined. However, there was no information 
available for the HPV-/p16+ group. There was also no clear definition of the terms 
‘excess’ and ‘social’ drinking.  
 
 The results show a similar pattern between the HPV-/p16- and HPV+/p16- 
groups, with 51% and 48% respectively defined as excess drinkers. Social drinkers in 
these two groups were 32% and 30% respectively. In comparison the HPV+/p16+ 
group had 23% excess drinkers and 60% social drinkers.  
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Figure 2.5: Drinking status of the sub-groups extracted from the Junor et al study. 
NB- Data for HPV-/p16+ group was not provided 
 
2.3.3.4 Primary tumour sites 
 
 There were 3 studies that provided detailed information on primary tumour 
sites for each sub-group (Evans et al, Hong et al and Junor et al). The study by Song 
et al only investigated tonsillar SCC tumours, and so was excluded in the analysis 
demonstrated in Figure 2.6. The most common primary site of tumours in all sub-
groups is the tonsil. There appears to be a higher proportion of tonsillar tumours 
(85%) in the HPV+/p16+ and HPV-/p16+ sub-groups, with a lower proportion of 
other oropharyngeal sites (4% and 0% respectively). In contrast the HPV-/p16- and 
HPV+/p16- show a higher percentage of other oropharyngeal sites, both 16%.  
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Figure 2.6: Primary tumour sites combined for each sub-group. NB- other 
oropharyngeal sites included soft palate, posterior pharyngeal wall, uvula or not 
otherwise specified. Data collated from Evans et al, Hong et al, and Junor et al 
 
2.3.3.5 TNM stage 
 
 The results in Figure 2.7 summarise the TNM staging for each sub-group. 
These were collated from Evans et al, Hong et al, Junor et al and Weinberger et al. 
There appears to be a higher proportion of Stage IV disease among the HPV-/p16+ 
and HPV+/p16+ groups of 62% and 72% respectively. Comparing the HPV-/p16- and 
HPV+/p16- groups the percentage of Stage IV disease is 49% and 48% respectively. 
The proportion of Stage I/II disease in the HPV-/p16- and HPV+/p16- groups is 25% 
and 24% respectively.  
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Figure 2.7: TNM staging for each sub-group. Data collated from Evans et al, Hong et 
al, Junor et al, and Weinberger et al 
 
2.3.3.6 Tumour grade 
 
 
Figure 2.8: Tumour grade summarised according to sub-groups. NB- Insufficient 
data for HPV-/p16+ sub-group. Data collated from Hong et al, Junor et al, and 
Weinberger et al 
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 Three studies provided sufficient data to summarise tumour grade (Figure 2.8) 
between sub-groups (Hong et al, Junor et al and Weinberger et al). Both the HPV-
/p16- and HPV+/p16- groups demonstrated a higher proportion of well/moderately-
differentiated tumours compared to HPV+/p16+ group, approximately 71%, 59% and 
39% respectively. In contrast the majority (54%) of HPV+/p16+ tumours were poorly 
differentiated, compared to HPV-/p16- (24%) and HPV+/p16- (26%).  
 
2.3.3.7 Primary treatment 
 
 
Figure 2.9: Differences in primary treatments between sub-groups. RT- radiotherapy, 
CT- chemotherapy. Data collated from Evans et al, Hong et al, Junor et al, Lewis et 
al, and Weinberger et al 
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summarised in Figure 2.9. The HPV-/p16+ (74%) and HPV+/p16+ (59%) groups had 
a higher percentage treated by surgery +/- radiotherapy +/- chemotherapy, compared 
to HPV-/p16- (53%) and HPV+/p16- (45%). In contrast a higher proportion of cases 
in the HPV+/p16- (35%) and HPV-/p16- (26%) groups were treated with radiotherapy 
alone, compared to the HPV+/p16+ (15%) and HPV-/p16+ groups (21%).    
 
2.3.4 Pooled prognostic outcomes 
 
 After discussion with the biostatistician a meta-analysis was deemed 
inappropriate due to the limited number of included studies and lack of adequate 
survival data (i.e. hazard ratios and confidence intervals). The prognostic outcomes in 
the selected studies were mainly presented in Kaplan-Meier survival plots. The 
following data have been extracted from these graphs in order to represent pooled 
prognostic outcomes, but statistical testing and significance would not be valid in this 
case.   
 
2.3.4.1 Disease-free survival 
 
The results in Tables 2.10 and 2.11 summarise the 3 and 5-year disease-free 
survival (DFS) rates respectively, produced by data extracted from Kaplan-Meier 
plots. The average DFS rates are graphically represented in Figure 2.10. The lowest 
DFS rate is shown in the HPV-/p16- group, with the HPV+/p16- group demonstrating 
comparable rates. In comparison the highest DFS rate is observed in the HPV+/p16+ 
group, with the HPV-/p16+ group also showing similar DFS rates.  
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Study 
 
3 year DFS 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Lewis et al 0.3 * 0.8 0.7 
Song et al 0.35 0.5 0.82 0.72 
Weinberger et al 0.3 0.35 0.76 * 
 
Average DFS 
 
0.32 
 
0.43 
 
0.79 
 
0.71 
Table 2.10: The 3 year DFS data extracted from Kaplan-Meier plots. *Data not 
provided 
 
Study 
 
5 year DFS 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Lewis et al 0.25 * 0.75 0.7 
Song et al 0.35 0.5 0.82 0.72 
Weinberger et al 0.15 0.13 0.76 * 
 
Average DFS 
 
0.25 
 
0.32 
 
0.78 
 
0.71 
Table 2.11: The 5 year DFS data extracted from Kaplan-Meier plots. *Data not 
provided 
 
 
Figure 2.10: Percentage mean DFS data pooled from the included studies, with 
standard error of means  
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2.3.4.2 Disease-specific survival 
 
Only 2 studies provided data for disease-specific survival (DSS), as 
summarised in Tables 2.12 and 2.13. These demonstrate the lowest DSS rates in the 
HPV-/p16- group, and the highest in the HPV+/p16+ group. Data for the other 
discordant groups were only provided in the separate papers, and therefore an average 
value could not be obtained. In the study by Hong et al the HPV+/p16- group had the 
lowest 3 and 5-year DSS of 61% and 58% respectively. The study by Lewis et al 
demonstrated similar DSS rates between the HPV-/p16+ and HPV+/p16+ groups. 
Study 
 
3 year DSS 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Hong et al 0.65 0.61 0.87 * 
Lewis et al 0.5 * 0.85 0.85 
 
Average DSS 
 
0.58 
 
N/A 
 
0.86 
 
N/A 
Table 2.12: The 3 year DSS data extracted from Kaplan-Meier plots. *Data not 
provided 
 
Study 
 
5 year DSS 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Hong et al 0.63 0.58 0.75 * 
Lewis et al 0.5 * 0.75 0.7 
 
Average DSS 
 
0.57 
 
N/A 
 
0.83 
 
N/A 
Table 2.13: The 5 year overall DSS extracted from Kaplan-Meier plots. *Data not 
provided 
 
2.3.4.3 Overall survival  
 
 The overall survival rates were extracted from Kaplan-Meier plots and 
summarised in Tables 2.14 and 2.15. Only the study by Stephen at al did not provide 
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data in this format. The average 3 and 5-year overall survival rates were lowest in the 
HPV-/p16- group, with the highest survival demonstrated in the HPV+/p16+ cohort. 
The discordant groups demonstrated survival rates between these two groups, with the 
HPV-/p16+ group revealing better overall survival rates compared to HPV+/p16- 
group. The pattern of overall survival between these groups is demonstrated in Figure 
2.11.   
Study 
 
3 year Overall Survival 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Evans et al 0.32 0.66 0.82 0.5 
Hong et al 0.55 0.55 0.85 * 
Junor et al (Cohort 1) 0.5 0.3 0.88 * 
Junor et al (Cohort 2) 0.35 0.75 0.9 * 
Lewis et al 0.3 * 0.8 0.8 
Song et al 0.5 0.5 0.95 0.7 
Weinberger et al 0.35 0.5 0.79 0.5 
 
Average OS 
 
0.41 
 
0.54 
 
0.86 
 
0.67 
Table 2.14: The 3 year overall survival data extracted from Kaplan-Meier plots. 
*Data not provided 
 
Study 
 
5 year Overall Survival 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Evans et al 0.24 0.5 0.75 0.5 
Hong et al 0.45 0.47 0.75 * 
Junor et al (Cohort 1) 0.4 0.18 0.82 * 
Junor et al (Cohort 2) 0.35 0.7 0.88 * 
Lewis et al 0.25 * 0.75 0.65 
Song et al 0.32 0.5 0.95 0.58 
Weinberger et al 0.2 0.18 0.79 0.5 
 
Average OS 
 
0.32 
 
0.42 
 
0.81 
 
0.58 
Table 2.15: The 5 year overall survival data extracted from Kaplan-Meier plots. 
*Data not provided 
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Figure 2.11: Percentage mean overall survival data pooled from the included studies, 
with standard error of means  
 
2.3.4.4 Hazard ratios 
 
 In total 5 studies reported hazard ratios (HR) of death from any cause. These 
are summarised in Table 2.16. The reference group used for each study varied, with 
three papers choosing the HPV-/p16- group and the other two studies referencing 
against the HPV+/p16+ group. The diversity of the presented data prevented a meta-
analysis. Comparing between studies, the best prognostic cohort appeared to be 
HPV+/p16+, with the HPV-/p16- the worst. The HPV+/p16- group showed similar 
HR compared to HPV-/p16-. In contrast the HPV-/p16+ group had lower HR values 
compared to HPV-/p16-.  
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Study 
 
Hazard Ratios 
(Confidence Intervals) 
 HPV-/p16- HPV+/p16- HPV+/p16+ HPV-/p16+ 
Hong et al Reference 
group 
1.04  
(0.77-1.41) 
0.33 
(0.25-0.45) 
* 
Lewis et al Reference 
group 
* 0.21 
(0.13-0.36) 
0.26 
(0.12-0.62) 
Weinberger et al Reference 
group 
0.80 
(0.40-1.80) 
0.19 
(0.10-0.70) 
* 
 
AVERAGE 
 
Reference 
 
0.92 
 
0.24 
 
N/A 
     
Song et al 5.34 
(1.11-25.81) 
3.05 
(0.27-33.89) 
Reference 
group 
3.23 
(0.65-16.15) 
Stephen et al 10.30 
(1.20-88.33) 
11.44 
(0.69-191.0) 
Reference 
group 
6.98 
(0.61-79.47) 
 
AVERAGE 
 
7.82 
 
7.23 
 
Reference 
 
5.12 
Table 2.16: Sub-group summary of hazard ratios of death from any cause. *Data not 
provided 
 
2.4 Discussion 
 
 There has been substantial research and increasing evidence in recent years of 
the role of HPV in HNSCC pathogenesis, particularly oropharyngeal cancers. Various 
studies indicate HPV positive HNSCC patients show significantly improved survival 
outcomes compared to HPV negative cases. Utilising HPV status as part of risk 
stratification and prognostic models requires a robust and accurate system of 
diagnosis. There are a number of diagnostic tests for detecting HPV, including p16 
expression, which were discussed in Chapter 1. While HPV and p16 status correlate 
in the majority of cases, the significance of the 2 discordant groups (HPV+/p16- and 
HPV-/p16+) remains unclear. This is the first systematic review to investigate the 
prognostic outcomes of OPC based on the HPV/p16 combination.  
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2.4.1 True positive vs. True negative  
 
 The majority of OPC cases in previous studies showed a strong correlation 
between HPV and p16 status, as summarised in Table 1.1. The studies included in this 
review found a similar pattern, with a total of 80% of cases either HPV+/p16+ (true 
positive) or HPV-/p16- (true negative).  
 
2.4.1.1 Demographics  
 
 Comparing between the true positive and true negative cohorts the results of 
this review demonstrate clear differences with the group characteristics and 
prognostic outcomes, as seen in previous studies. The sex ratio in the HPV-/p16- 
cohort was 3:1 (male: female) compared to 4:1 with HPV+/p16+. The higher 
proportion of male subjects in HNSCC is well established (Langevin et al., 2011). 
The study of OPC cases by Ang et al showed a similar increased proportion of male 
subjects in the HPV positive cohort compared to HPV negative (86.4% vs. 79.5% 
respectively), but this was not statistically significant (Ang et al., 2010). We also 
found a difference in mean age at diagnosis of 61 years (true negatives) and 53 years 
(true positives). Previous studies have demonstrated statistically significant 
differences in the average ages between HPV positive and HPV negative cases (Ang 
et al., 2010, Chaturvedi et al., 2011).   
 
 The typical risk factors associated with HNSCC are smoking and alcohol 
consumption, and these showed variations between the two cohorts. In the HPV-/p16- 
group 81% had a positive smoking history, compared to 59% in the HPV+/p16+ 
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group. However, excluding the cases with an unknown smoking history the figures 
are 96% and 71% respectively. The RTOG 0129 data (Ang et al., 2010) of OPC cases 
reported on the median years of tobacco exposure, with 36.5 years in the HPV 
negative cohort compared to 12.2 years in HPV positive cases (p<0.001). In this 
review we also found a discrepancy in alcohol exposure between the true HPV 
positive and negative cohorts, albeit based on only one study by Junor et al. On 
average 51% of HPV-/p16- cases were classified as excessive drinkers, compared 
with 23% of HPV+/p16+ cases. Exposure to both alcohol and smoking is thought to 
play a synergistic effect on the risk of cancer (Castellsague et al., 2004).  
   
 Within the oropharynx several anatomical sub-sites exist, and our data 
illustrates a difference between the HPV-/p16- and HPV+/p16+ groups. In total 84% 
HPV-/p16- cases were either tonsil or base of tongue tumours, compared to 96% of 
HPV+/p16+. The remaining cases were located in other oropharyngeal sites including 
uvula, posterior pharyngeal wall and soft palate. In a Swedish study of OPC cases the 
prevalence of HPV at the different sub-sites were analysed (Attner, 2013). The 
majority of tonsillar and base of tongue SCC were HPV positive (79% and 75% 
respectively), whereas 25% of other OPC sites were positive. In another Swedish 
study focusing on OPC cases other than tonsil or base of tongue sites, 69% cases were 
HPV-/p16- (Marklund et al., 2012). Furthermore the authors found that HPV or p16 
status in these sub-sites showed no prognostic significance.   
 
 There is evidence that HPV-related oropharyngeal cancers present at a more 
advanced disease stage, with a lower T-stage and higher N-stage (Elrefaey et al., 
2014, Psyrri et al., 2011). This review found 25% HPV-/p16- cohort were TNM stage 
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I/II, compared to 8% in the HPV+/p16+ group. The majority of HPV+/p16+ cases 
were TNM stage IV compared to HPV-/p16- (71% and 49% respectively). In a recent 
UK study of OPC cases there was a statistically significant difference in TNM staging 
between the HPV negative and HPV positive cohorts, with 51.3% and 80.3% 
respectively classified as stage IV (Ward et al., 2014). Our review also demonstrated 
that HPV+/p16+ cases had a greater proportion of poorly differentiated tumours 
compared to HPV-/p16- (54% and 24% respectively). Other studies have shown HPV 
positive OPC associated with poorly differentiated tumours (Gillison et al., 2000).  
 
 In summary our review confirms results from previous studies regarding the 
differences in demographics and risk profile between true positive and negative OPC. 
The typical true positive patient would be male, younger, social drinker, and less 
likely to be a smoker. The true positive tumours are more likely to be tonsil or base of 
tongue, diagnosed at a more advanced stage, and poorly differentiated. Whereas the 
true negative patient would likely be an older male, with a positive smoking history 
and an excessive drinker with a greater chance of the primary tumour located in other 
oropharyngeal sites, and presenting at an earlier stage with more a favourable tumour 
grade.  
 
2.4.1.2 Prognostic outcomes 
 
 The results of this systematic review concur with numerous studies and 
reviews on the subject of HPV positivity and improved prognostic profiles. The 3 and 
5-year DFS rates for HPV-/p16- cases were 32% and 25% respectively. In contrast 
the figures for HPV+/p16+ are far more favourable at 79% and 78% respectively. 
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Similarly the 3 and 5-year DSS rates for HPV-/p16- were 58% and 57%, compared to 
HPV+/p16+ of 86% and 83%. The same pattern is observed for 3 and 5-year overall 
survival rates, with HPV-/p16- values of 41% and 32%, and HPV+/p16+ of 86% and 
81%.  
 
 Five studies in this systematic review provided data on HR of death, with all 
showing a significantly better HR for the HPV+/p16+ group. Referencing against 
HPV-/p16- there was on average a 76% reduced risk of death for the HPV+/p16+ 
group (average HR 0.24). There were 2 papers that referenced against the HPV+/p16+ 
group, with the average HR for HPV-/p16- of 7.82. In comparison the systematic 
review by Ragin et al demonstrated a 28% (HR 0.72) reduced risk of death for HPV 
positive OPC cases compared to HPV negative (Ragin et al., 2007b). In the meta-
analysis by Dayyani et al the HR of HPV positive OPC was 0.40 (Dayyani et al., 
2010), which was statistically significant (p<0.0001). Another review article found 
HPV positive OPC had a pooled HR of 0.47 (O'Rorke et al., 2012).  
 
The demographic differences described between the two main groups of OPC 
are likely to influence the prognostic outcomes. The younger HPV+/p16+ cohort has 
less association to smoking and alcohol, both of which are classified as group 1 
carcinogens (IARC, 2014). There is evidence that HPV negative tumours are more 
likely to harbour critical mutations of genes related to cell survival, such as p53. One 
review article (Dayyani et al., 2010) reported p53 mutations in HPV positive HNSCC 
were statistically less likely compared to HPV negative tumours (Adjusted OR = 0.21, 
p=0.015). Besides the differences in risk factors between these groups, the younger 
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HPV+/p16+ patient is less likely to present with multiple co-morbidities, which can 
also influence treatment options and survival outcomes.  
 
However, one paradox of these cancers is that HPV positive OPC typically 
present at a more advanced stage and with poorly differentiated tumours compared to 
HPV negative cases. This pattern was also demonstrated in our review in the 
HPV+/p16+ cohort. Logically such tumours would be expected to have poorer 
response to treatment and worse prognosis, but the data contradicts this notion. 
Therefore other undefined factors are likely to play a role in the natural history of 
HPV positive disease. Theoretically the link between smoking and alcohol with 
regards to increased risk of mutations may render the HPV negative tumours cells 
more molecularly unstable, and thus less likely to respond well to treatments. 
Moreover, the overexpression of p16 in the majority of HPV positive tumours is 
likely to influence the prognostic outcomes. The role of p16 in normal cell function 
was described in Section 1.2.3.4. Previous studies have demonstrated p16 as an 
independent positive prognostic indicator in OPC (Weinberger et al., 2004, Fischer et 
al., 2010).  
 
2.4.2 Relevance of discordant groups  
 
 The primary aim of this systematic review was to establish the prognostic 
significance of the discordant groups, HPV+/p16- and HPV-/p16+. The results have 
demonstrated an interesting pattern, with each discordant group appearing to correlate 
closely with the true negative and positive cohorts respectively.   
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2.4.2.1 HPV+/p16- vs. True negative 
 
  The descriptive analysis has shown that the HPV+/p16- discordant group 
share similar characteristics to the HPV-/p16- group (true negatives). The HPV+/p16- 
cohort had a sex ratio of 2.45:1 (M: F), compared to 3:1 in the true negative group. 
The average mean ages were almost identical at 60.4 years and 61 years respectively.  
 
 On average 71% of the HPV+/p16- group had a positive smoking history, 
compared to 81% in the HPV-/p16- cohort. Based on the study by Junor et al alcohol 
intake was almost identical between the two groups, with approximately 48% of the 
HPV+/p16- group classified as excess drinkers and 30% social drinkers, and for 
HPV-/p16- these were 51% and 32% respectively. The proportions in site of primary 
tumour were the same in both groups, with 84% tonsil or base of tongue and the 
remaining in other oropharyngeal sites.  
 
 Patterns in TNM staging were almost identical; 24% HPV+/p16- were stage 
I/II, with 25% for the true negative cohort. Similarly 48% and 49% were TNM stage 
IV respectively. While 59% of HPV+/p16- tumours were well or moderately 
differentiated, compared to 71% for true negative tumours. In comparison 26% 
HPV+/p16- tumours were poorly differentiated, which was similar to the true 
negatives (24%).  
 
 As well as demographic profiles, the two groups also share comparable poorer 
prognostic outcomes. The 3 and 5-year DFS rates for HPV+/p16- were 0.43 and 0.32 
respectively, and 0.32 and 0.25 for the true negative cohort. The average 3 and 5-year 
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overall survival rates for HPV+/p16- were 0.54 and 0.42, compared to 0.41 and 0.32 
for HPV-/p16-. The average HR for death for HPV+/p16- when referenced against 
HPV-/p16- was 0.92. Similarly when referenced against HPV+/p16+ the average HR 
for HPV+/p16- was 7.23, compared to 7.82 for HPV-/p16-.  
 
 In summary the demographic profiles are comparable between HPV+/p16- 
and the true negative cohort. The prognostic outcomes for HPV+/p16- appear to 
correlate closely to the HPV-/p16- group, although the latter appear to have the worst 
prognosis of all the sub-groups.  
 
According to these results the HPV status of tumours may not necessarily 
indicate a better prognosis, particularly in the sub-group of p16 negative cases. As 
with the true negative cohort, the prognosis of the HPV+/p16- group maybe 
influenced by a more unfavourable demographic and risk factor profile. The negative 
status of p16 for these two groups can also contribute to the poorer outcomes 
observed. The lack of p16 overexpression in the HPV+/p16- discordant group can be 
due to three reasons. Firstly, previous studies have reported p16 gene alterations or 
deletions in a significant proportion of HNC (Liggett et al., 1998). Thus despite a 
HPV infection the overexpression of p16 would be prevented in such tumours. 
Furthermore loss of normal p16 function could render the host cells more susceptible 
to tumourgenesis. Secondly, the HPV+/p16- group may represent true negative 
tumours with false positive HPV testing, particularly with the highly sensitive PCR 
method. False positive testing can occur in contaminated samples or HPV infection 
unrelated to tumour pathogenesis (i.e. non-integrated HPV genome). Therefore it is 
unclear if the HPV+/p16- cohort represents a true discordant group, although survival 
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outcomes do appear somewhat more favourable compared to HPV-/p16-. Finally, 
categorising these groups relies on various laboratory tests and cut-off points, which 
do differ between the included studies. Also without a clear and uniform definition for 
each subgroup there is likely to be overlap among the cohorts. This can impact on the 
results of the discordant groups as well as the true positive and negative subgroups.   
 
2.4.2.2 HPV-/p16+ vs. True positive 
 
 The HPV-/p16+ group demonstrated the highest sex ratio difference of 
approximately 9:1 male to female, followed by the true positive group at 4:1. Both 
these groups had similar mean ages, 52.2 years for HPV-/p16+ compared to 55.3 
years for HPV+/p16+. Positive smoking history was observed in 79% of the 
discordant HPV-/p16+ group, compared to 59% for HPV+/p16+.  
 
 There were similarities between the primary tumour sites; 100% of HPV-
/p16+ group were either tonsil or base of tongue tumours, compared to 96% for the 
true positive cohort. Similarly the pattern of TNM staging showed 15% HPV-/p16+ 
classed as stage I/II and 8% of HPV+/p16+, while the majority in both groups were 
stage IV (62% and 71% respectively). Data was unavailable to compare tumour 
grades.  
 
 Prognostically these groups also appeared to correlate. While the true positives 
demonstrated the best outcomes for all parameters, the HPV-/p16+ group also had 
relatively better prognosis compared to the HPV-/p16- and HPV+/p16- cohorts. The 3 
and 5-year DFS rates for HPV-/p16+ were both 0.71, while the true positive group 
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were 0.79 and 0.78 respectively. Whereas the overall survival rates were 0.67 and 
0.58 respectively for the discordant group, the true positives were 0.86 and 0.81. The 
study by Lewis et al provided HR values of 0.26 and 0.21 for HPV-/p16+ and 
HPV+/p16+ respectively, when referenced against HPV-/p16-. Two other studies 
provided HR values referenced against HPV+/p16+, with a combined average HR of 
5.12 for HPV-/p16+.  
 
 It appears that the discordant HPV-/p16+ group does share similar 
demographic and prognostic profiles compared to the true positive cohort. Both 
groups appear in a younger population, are strongly associated with tonsil or base of 
tongue tumours, and present at a more advanced disease stage. However, while 
prognosis in HPV-/p16+ appears more favourable in comparison to HPV-/p16- and 
HPV+/p16-, there is still a difference in relation to the true positives. This difference 
could be explained partly by the higher rate of smokers in the HPV-/p16+ cohort. 
Several possibilities exist regarding the nature of the discordant HPV-/p16+ group. 
This cohort may represent HPV+/p16+ tumours with a false negative HPV test, 
particularly if low numbers of HPV particles exist in the tumour sample. Also the 
HPV tests utilised by the included studies may have missed other HPV types not 
detected by conventional PCR or ISH methods. Alternatively p16 overexpression may 
not be driven by HPV infection but by another unknown variable, such as dysfunction 
in the pRb pathway leading to loss of p16 feedback control. Like HPV+/p16- it is 
unclear if HPV-/p16+ tumours represent a true discordant group with specific 
biological qualities.  
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2.4.3 Prognostic models  
 
 This systematic review has highlighted the varying patterns of 4 sub-groups of 
oropharyngeal cancers according to HPV and p16 status. The HPV+/p16+ patients 
clearly have more favourable demographics and prognostic outcomes, and the HPV-
/p16- are related to poorer demographic and risk factor profiles and associated with 
the worst prognosis. The two discordant groups have demonstrated similar profiles 
related to the true positive and negative cohorts respectively, with HPV-/p16+ 
patients revealing better prognostic outcomes compared to HPV+/p16-. Therefore the 
p16 status of OPC tumours appears more likely to predict better prognosis than HPV 
status alone, and adds weight to the argument of utilising p16 testing as a surrogate 
marker of HPV-related cancers (El-Naggar et al., 2012).  
 
 Prognostic models of oropharyngeal cancers can be potentially complex, 
particularly if focused on the multiple parameters for individual patients. The ultimate 
model would be applicable to the majority of patients and highly accurate. However, 
our results indicate that HPV status maybe missing sub-groups of patients with 
varying survival outcomes. For example, the model proposed by Ang et al (Figure 
1.6) initially separates tumours according to HPV status. Therefore the HPV-/p16+ 
group would be classed as intermediate or high risk, depending on smoking history 
and T-stage. Similarly the HPV+/p16- would be considered low or intermediate risk 
according to smoking history and N-stage. The accurate classification of these sub-
groups can potentially improve disease outcomes when considering de-escalation or 
more aggressive treatment options according to risk stratification.  
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 Considering the substantial evidence of improved outcomes in HPV-related 
cancers, it is only a matter of time before HPV status is universally included in 
disease staging and risk stratification. Therefore accurate testing is required to 
identify HPV relevant disease. This can include combining p16 testing with PCR and 
ISH. Previously there have been algorithms proposed for HNSCC HPV testing, which 
claim 100% sensitivity and specificity by utilising p16 IHC and PCR (Smeets et al., 
2007). Future utilisation of accurate testing algorithms will depend on costs and 
resource availability. 
       
2.4.4 Limitations of systematic review  
 
 In this review we aimed to ensure our searches and selection of relevant 
studies was comprehensive. However, the accuracy of such searches is limited by the 
quality of the databases themselves and the search terms used. For example, we found 
most studies abbreviated oropharyngeal cancer as OPSCC, while a minority 
abbreviated as OSCC. This could impact on the search results. We did ensure a more 
precise search strategy by utilising two independent reviewers. The inter-rater 
reliability scores for title and abstract selection were rated as moderate (0.498) and 
substantial (0.794) respectively, according to the Kappa score. We intended to include 
all studies irrespective of language. However, two studies from China and Japan 
could not be obtained. Only one study was included from Asia.  
 
 We found the quality of the included studies was variable, with an average 
range from 4.5 to 11 (out of 12). The included studies were all retrospective cohorts, 
which are level IIb evidence. The effect of each study on the overall results can 
Chapter 2- Systematic Review and Descriptive Analysis 
 
 91 
normally be assessed by sensitivity analysis. However, due to the limited data and 
number of included studies a formal meta-analysis was not possible. We were also 
unable to assess the statistical significance of our results.  
 
 Another limitation in this review is the variation in p16 and HPV testing 
among the studies. There was no consensus on defining p16 positivity, with a 
discrepancy in staining cut-off points. Also while some studies utilised more than one 
pathologist for p16 scoring others did not mention this. Furthermore, different HPV 
testing methods were used in each study. Therefore, we could not assess the impact of 
these laboratory tests on the overall results. Ideally a sensitivity analysis would have 
been utilised if a meta-analysis were possible, in order to assess the impact of 
different study variables on the outcome of the review. 
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3.1 Introduction 
 
 Drug re-purposing has the potential to identify novel therapies for various 
conditions, including cancers. Cancer treatment, such as chemotherapy, is usually 
associated with significant side effects. These include nausea and vomiting, bone 
marrow suppression, loss of hair and mucositis . However, novel therapies using drug 
re-purposing may offer target drugs with a more favourable side effects profile.  
 
 Various drug re-purposing methods exist, such as serendipitous discoveries 
with current drugs or computational methods to predict new drug targets. In another 
systematic method high-throughput screening (HTS) can be utilised by automated 
cell-based assays and drug libraries. This technique has been employed, for instance, 
in one study to identify potential drug targets for treating thyroid cancers (Zhang et 
al., 2012). The authors performed HTS with a Luciferase-coupled ATP quantification 
assay using TPC-1 (human papillary thyroid cancer cell line) and used a publically 
accessible drug library consisting of over 2800 small-molecule compounds. They 
identified 2 drug targets (Bortezomib and Ouabin) possessing both high efficacy, IC50 
(half maximal inhibitory concentration) values within the nanomolar range and within 
clinically achievable drug serum concentration. These drug targets were further tested 
with various thyroid cancer cell lines using proliferation, caspase and flow cytometry 
assays. Both agents demonstrated antiproliferative effects across all the selected 
thyroid cancer cell lines, as well as increasing apoptotic activity compared to vehicle 
control. Furthermore Ouabin showed evidence of cell cycle arrest (increased G2/M 
phase) during flow cytometry analysis. 
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Similarly a systematic approach to drug re-purposing has been utilised for the 
AcceleraTED Platform (Accelerated Translation of therapeutic agents and Emerging 
Devices in Head and Neck and Thyroid cancer). The aims of AcceleraTED are to 
rapidly increase available therapies in HNC management, and develop personalised 
treatments (Mehanna, 2014). The stages of AcceleraTED are screening, confirmation 
and validation (Figure 3.1). Initial Phase 1 screening involves a systematic review of 
numerous sources to identify suitable HNC cell lines and both collaborative and 
commercial drug libraries. Next a HTS cell-based proliferation assay is used to 
identify potential drug candidates. Further testing involves a validating proliferation 
assay, flow cytometry, migration and clonogenic assays. In Phase 2 drug 
combinations are tested for the previously identified drugs, and also conventional 
treatments already in clinical practice for the disease are included. Drug targets that 
are identified with therapeutic potential are then tested in appropriate mouse models 
before exploring personalised treatments. Finally, Phase 3 involves validation of drug 
targets in clinical trials prior to introduction into clinical practice.  
 
The aim of the current study was to assess 3 drug targets that emerged from 
the primary screen; INH001, INH002 and INH003. These drugs were identified from 
the initial HTS and appeared to be effective in both our selected HNC cell lines, and 
this will be discussed in further detail. Several cell-based assays were utilised to 
examine the effects of these drug targets against the two HNC cell lines.  
 
INH001 belongs to the group of water-soluble vitamins. INH002 is an anti-
hypertensive drug with alpha-adrenergic agonist activity. INH003 is an anti-
helminthic drug effective against tapeworm infections.  
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Figure 3.1: Illustration of the AcceleraTED platform, which includes Phase 1 (drug 
target screening), Phase 2 (target drug confirmation) and Phase 3 (validation in 
clinical trials) (Mehanna, 2014) 
  
3.2 Materials and Methods 
 
All preparations and experiments were performed in sterile conditions using a 
HERAsafe Class II biological safety cabinet (Thermo Scientific- S/N 40927282). 
Unless stated, incubations during experiments were at 37oC and 5% CO2.     
 
 
3.2.1 Cell lines 
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3.2.1.1 Cell line characteristics  
 
Candidate HNC cell lines were selected from commercially available sources, 
where possible. Ideal cells required the ability to grow a monolayer in culture, and 
were also chosen according to HPV status.  
 
SCC040 (UPCI-SCC-040) is a HPV negative cell line, purchased from The 
Leibniz Institute DSMZ-Germany (catalogue no. ACC-660). The cell line was 
originally deposited at the University of Pittsburgh Medical Centre (DSMZ, 2015). 
SCC040 was established from a 50-year-old Caucasian male, non-smoker with a 
history of alcohol intake, who died of disease. These cells are primary, moderately 
differentiated tongue squamous cell carcinoma=; T2N2 and TNM stage 4 (Martin et 
al., 2008). The SCC040 cell line possesses wild-type p53. Doubling time was 
calculated to be between 21-25 hours (Dr Rachel Watkins, InHANSE).  
 
VU147 (93-VU-147T) is a non-commercial HPV positive cell line, and was a 
kind gift from Dr Sally Roberts (University of Birmingham, West Midlands, UK).  
The cell line was originally deposited at the VU University Amsterdam (Hermsen et 
al., 1996). VU147 was established from a 58-year-old male, with a history of smoking 
and alcohol intake. These cells are primary, moderately differentiated floor of mouth 
SCC; T4N2 (Hermsen et al., 1996). VU147 cells contain HPV-16 DNA, and express 
HPV-16 E6/E7 viral oncoproteins (Rampias et al., 2009). Doubling time was 
calculated to be between 33-45 hours (Dr Rachel Watkins, InHANSE). 
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3.2.1.2 Cell culture protocol 
 
Cell culture medium was prepared using Dulbecco’s Modified Eagle’s 
Medium-HEPES Modification (DMEM- Sigma, D6171), and supplemented with 10% 
fetal bovine serum (FBS- Sigma, F7524), 1% L-Glutamine (2mM- Gibco, 25030-
024), 1% Penicillin (50U/ml) with Streptomycin (50ug/ml)- (Gibco, 15070-063), and 
1% (X100) non-essential amino acids (NEAA- Sigma, M7145).  
 
 Cells were maintained in T75 culture flasks (Corning Incorporated, 430641), 
at 37oC and 5% CO2. To prepare for counting or passaging cells were washed in PBS 
(phosphate-buffered saline), and re-suspended using TrypLE Express solution (1X, 
Gibco, 12605-010). Cell centrifuging was performed using a Sarstedt LC24 centrifuge 
(S/N 730513-7), and set at 1,100 rpm for 4 minutes to obtain a cell pellet. The cell 
pellet was re-suspended in DMEM and was split according to planned experiment 
requirements  (e.g. 1:5). Cell passage was performed 2-3 times weekly, depending on 
cell confluence.  
 
3.2.1.3 Counting cells 
 
In order to count cells 0.4% Trypan blue stain (Life Technologies, T10282) 
was used according to manufacturer’s instructions. Cell counts were obtained using a 
Countess cell counting chamber slide (Invitrogen, C10283) and Countess automated 
cell counter (Invitrogen, C10281), which provided a digital reading of live cell count 
per ml. Viability of cells was typically 95% or above.  
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3.2.1.4 Authentication of cells 
 
The SCC040 cell line was authenticated in June 2014 by DNA profiling (DDC 
DNA Diagnostic Centre, London, UK). The VU147 cell line is not commercially 
available, and therefore could not be authenticated by DNA profiling. Instead PCR 
was performed to authenticate the HPV status of the two cell lines, and described 
below.  
 
Cells were first prepared for counting (Section 3.2.1.3). Using the DNeasy 
Blood and Tissue Kit (Qiagen, 69504), steps were followed as per manufacturer’s 
instructions. Briefly, 1ml of cell volume (maximum recommended 5x106 cells) was 
transferred to a micro-tube and centrifuged in an Eppendorf Centrifuge 5424 (S/N 
5424CJ050429) at 200 rpm for 5 minutes. Cell pellets were re-suspended in 200µl 
PBS, and supplemented with 20µl proteinase K and 200µl Buffer AL. The solution 
was mixed by vortexing using a Whirlmixer (Fisons Scientific Apparatus, 
WM/250/SC). Samples were then placed in a water bath at 56oC for 10 minutes. A 
further 200µl 100% ethanol was added and samples vortexed. The mixture was 
transferred to a DNeasy Mini spin column, placed within a 2ml collection tube. Tubes 
were centrifuged at 8000 rpm for 1 minute, and the spin column was transferred into a 
new collection tube. The spin column was treated similarly with Buffer AW1 then 
Buffer AW2. Finally, DNA was eluted by addition of Buffer AE and centrifuging.  
 
 DNA yield was quantified by sampling a 1µl volume using the Nanodrop NP-
1000 Spectrophotometer (S/N 1705). The spectrophotometer was calibrated with the 
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eluting Buffer AE. Samples were analysed with the Nanodrop 3300 software (Thermo 
Fisher Scientific, Version 2.7.0).  
 
 The PCR reaction mixture included 12.5µl GoTaq Hot Start Green Master 
Mix (Promega, MF122), 30ng DNA template or water (negative control), 1.25µl 
forward primer (Table 3.1), 1.25µl reverse primer, and 9µl nuclease-free water 
(Promega, P119A). PCR controls included previously prepared and tested VU147 
sample (HPV positive cell) as a positive control, and C33a sample (HPV negative 
cell) and water as negative controls. Since quantification of PCR product was not 
intended an endogenous positive control (e.g. GAPDH) was not included.  
 
Forward primer 
 
 
5’-AATGTTTCAGGACCCACAGG-3’ 
 
Reverse primer 
 
 
5’-CCCGAAAAGCAAAGTCATATACC-3’ 
Table 3.1: HPV 16 E6 primers (Sigma), kindly provided by Dr Steven Lee (University 
of Birmingham, UK) 
 
 The PCR reaction was performed using the Geneamp PCR System 9700 (PE 
Applied Biosystems). Conditions were set as follows: 95°C for 15 minutes; 35 cycles 
of 95°C for 30 seconds, 58°C for 30 seconds, 72°C for 40 seconds; 72°C for 10 
minutes; 4°C hold. Gel electrophoresis was prepared in 2% UltraPore Agarose 
(Invitrogen, 16500_500) added to 50ml of 1X TAE (Tris-acetate-EDTA) buffer, with 
the addition of 5µl SYBR Safe DNA gel stain (Invitrogen, 533102). Each 10µl PCR 
sample was supplemented with 2µl Gel Loading Dye Blue (Biolabs, B7021S). In 
addition a 100bp DNA ladder (Biolabs, N3231S) was run with the samples, and gel 
electrophoresis performed at 110 volts for 30 minutes. An image of the gel was taken 
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under UV light using the Geneflow Geneflask (S/N 1055) and Pulnix TM-300 camera 
(S/N 002342).  
 
3.2.2 Drug Targets 
 
3.2.2.1 1nitial screening  
 
Drug targets were screened from a drug library (FMC) kindly provided by Dr 
Farhat Khanim (University of Birmingham, West Midlands, UK), which included 100 
off-patent licenced drugs. Initial screening was performed by robotic HTS using 
proliferation assays (Dr Peter Rae, InHANSE), to identify target candidates. The 
results were standardised according to effect on proliferation compared to untreated 
control, and graded according to efficacy (Table 3.2). Drug targets were selected if 
they had moderate efficacy or better, and were effective in the selected cell lines.   
Efficacy % Reduction in proliferation vs. untreated control 
Increased proliferation effect <0% 
Poor/No effect 0-25% 
Moderate effect 26-50% 
Good effect 51-75% 
Considerable effect 76-100% 
Table 3.2: Effect of drug target on proliferation compared to untreated control 
 
3.2.2.2 Preparing drugs  
 
Drug targets to be assessed were pre-prepared by Dr Peter Rae (InHANSE) 
into X10,000 stock aliquots, and stored at -20oC until required. During experiments 
all target drugs underwent serial dilutions using DMEM to make X1 final solution, 
which corresponded to peak serum concentration (clinically achievable 
concentration).  
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INH001 (Sigma) was prepared to a 950mM stock in water, and diluted to a 
95µM working solution. INH002 (Sigma) was prepared as a 57.2mM stock in DMSO 
(Dimethyl-Sulfoxide Hybri-Max, Sigma- D2650), and diluted to 5.72µM working 
solution. INH003 (Sigma) was prepared as a 32mM stock in ethanol, and had a 
working concentration of 3.2µM.  
 
Cisplatin was included as a positive control and allows comparison to standard 
treatment. During experiments 3mg Cisplatin powder (Biovision, 1550-1000) was 
dissolved in 1ml of DMSO to form a 10,000µM solution. Serial dilutions were 
performed in DMEM to a final concentration of 5µM, 10µM or 15µM solutions. 
These Cisplatin concentrations were selected based on IC50 data and previous 
optimisation experiments performed on SCC040 and VU147 cells for the 
AcceleraTED project (InHANSE).  
 
3.2.3 Proliferation Assay 
 
3.2.3.1 Optimisation 
 
 The alamarBlue (Invitrogen, DAL1100-463418) cell viability assay was 
utilised to quantitatively measure proliferation of the cells. This assay measures the 
conversion of Resazurin (blue, weakly fluorescent) to Resorufin (red, highly 
fluorescent), which is proportional to cell activity (alamarBlue, 2015). The assay was 
initially optimised, to determine the appropriate conditions for each cell line 
(AcceleraTED, InHANSE). Briefly, this involved plating cells at various seeding 
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densities (range 800 to 5000 cells/well) in 96 well plates, to determine which density 
will grow to 80-90% confluence by 72 hours. The 72-hour time-point was selected as 
an appropriate end-point, in order to adequately assess drug treatment effects in 
subsequent experiments. Cells were pre-seeded the day before. Three independent 
laboratory staff performed optimisation, and all densities performed in triplicate. 
Optimum cell density for SCC040 was found to be 2,500 cell/well, and VU147 was 
4000 cells/well.  
 
Furthermore, alamarBlue reagent was incubated at various time-points (2, 4, 6, 
8 hours), to determine appropriate RFU (relative fluorescence units) readings. The 4-
hour incubation period was subsequently chosen for both cell lines.  
 
3.2.3.2 Protocol 
 
 Cells were first prepared for counting (Section 3.2.1.3). Live cell counts were 
used to calculate serial dilutions to obtain the final cell densities. Cells were pre-
seeded in a Costar 96 well plate (Corning Incorporated, 3596) the day before. A 100µl 
volume was pipetted into corresponding wells into 3 separate plates (24, 48, 72 hours 
plates). A further 3 plates were seeded with DMEM only, in order to measure 
alamarBlue background readings to calculate the effect of drugs only on plate 
readings.  
 
On day two fresh drug and vehicle-only controls dilutions were performed to 
obtain a X2 (two times the final concentration) solution. Cisplatin was freshly 
prepared (Section 3.2.2.2), and diluted to provide X2 working solution (10µM, 20µM, 
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30µM). For each plate, 100µl of DMEM was added to the first column, as a negative 
control. Corresponding columns were then treated with each condition, with the 
addition of 100µl volume, with a final drug/control concentration of X1 (final well 
volume = 200µl). Each condition had triplicate wells. Plates were then incubated for 
24, 48 or 72 hours.  
 
 Following incubation, 20µl of alamarBlue reagent was added to the required 
plates 4 hours prior to the end-point (20 hours > 24 hours, 44 hours > 48 hours, 68 
hours > 72 hours) as per the manufacturers instructions. The lids were then removed 
from the plates and placed in the Wallac 1420 Victor2 Multilabel Counter (S/N 
29981517). Plates were read at 550/590nm 0.1s fluorescence using the Wallac 1420 
Manager (Perkin Elmer Life Sciences, Version 3.00.0.53). This provided relative 
fluorescence values (RFU). All values were adjusted by deducting the results from the 
media-only plates, which measured background alamarBlue values. Using the 
triplicate results for each condition an average value was calculated for the technical 
repeats. The average results were then converted to a percentage against the untreated 
control.  
 
Experiments were repeated on three separate occasions to provide 
biological/experimental repeats, and an average calculated from percentage values.  
  
3.2.4 Migration Assay 
 
3.2.4.1 Optimisation 
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 The migration assay, also known as wound healing or scratch wound assay, 
was optimised to determine the appropriate seeding cell density for each cell line. In 
order to perform the assay ~100% confluence was required at 48-hour incubation, to 
assess migration once a wound was created.  
 
 Cells were prepared for counting (Section 3.2.1.3), and serial dilutions 
performed to obtain final cell densities ranging from 50,000 cells/well to 300,000 
cells/well (50,000 increments). Seeding of cells was performed in a Costar 12 well 
plate (Corning Incorporated, 3513). Triplicate wells were set up for each cell density. 
Plates were incubated and representative images taken at 24, 48, 72 and 96 hours. To 
achieve 100% confluence at 48 hours, the required seeding density for SCC040 was 
250,000 cells/ml. VU147 cells did not appear to reach 100% confluence by 48 hours 
during optimisation, which could partly be due to the increased doubling time for this 
cell line. Therefore the migration assay could not be performed on VU147 cells.  
 
3.2.4.2 Protocol 
 
 Cells were prepared for counting (Section 3.2.1.3). Serial dilutions were 
performed to obtain a final SCC040 cell concentration of 250,000 cells/ml. Seeding of 
cells with 1ml cell volume was performed in a 12-well plate. After 24 hours cell 
confluence was assessed to ensure ~100% confluence. The media was then replaced 
with fresh media, and X2 drug dilutions and controls were prepared. To each 
corresponding well 1ml of drug or control was added to a final concentration of X1. 
Plates were incubated for 24 hours.  
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 Following incubation wounds were created using a sterile 10µl pipette tip, and 
changed between wells. Media and drugs/controls were then replaced to minimise cell 
debris within the wells. Imaging of plates was carried out using a Nikon Eclipse 
TS100 microscope (10x magnification), Q-Imaging Rolera-XR camera and Q-Capture 
software (2011 Quantitative Imaging Corporation, Version 2.9.13). Prior to imaging 3 
points were marked on the underside of each well using a permanent marker pen, to 
ensure accurate and reproducible points to image. Representative images were taken 
at three time points (0, 6, 24 hours). The final image was performed once the media-
only control wells appeared to show complete wound closure, at approximately 24 
hours.  
 
Images of wounds were analysed using Image J (National Institute of Health, 
USA, Version 1.48), which enabled measurement of wound areas. First an average 
value for each well was calculated, and then an average from the technical repeats. 
Experiments were repeated on three separate occasions to provide biological repeats, 
and an average calculated. The final averages were used to analyse wound closure at 
24 hours against 0 hours, to provide percentage wound closure at 24 hours for each 
biological repeat. Percentages were averaged (N=3) and adjusted against untreated 
control.   
 
3.2.5 Cell cycle Flow Cytometry Assay 
 
3.2.5.1 Optimisation 
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 Flow cytometry was utilised to perform Propidium Iodide (PI) cell cycle 
analysis. Optimisation for each cell line was required to determine the appropriate 
seeding density. The ideal density for cell cycle analysis would enable adequate cell 
growth but avoid over-confluence (approximately 70% confluence).  
 
Cells were prepared for counting (Section 3.2.1.3), and serial dilutions 
performed to obtain final cell densities ranging from 50,000 cells/well to 300,000 
cells/well (50,000 increments). Seeding of cells was performed in a Costar 6 well 
plate (Corning Incorporated, 3516). Triplicate wells were set up for each cell density. 
Plates were incubated and representative images taken at 24, 48, 72 and 96 hours. 
Selected seeding density for SCC040 was 100,000 cells/well (50,000 cells/ml), and 
was optimised by Dr Rachel Watkins (InHANSE). The cell density for VU147 was 
150,000 cells/well (75,000 cells/ml).  
 
Optimisation of time-points for drug treatment was performed (16, 24, 48, 72 
hours). These time-points were chosen based on the optimisation and results of the 
proliferation assay.  The final selected time points were 16 and 72 hours. The 16-hour 
time-point showed no significant effect on the cell cycle analysis with both the drugs 
and positive controls, whereas 72 hours allowed sufficient time for target drugs to 
demonstrate an effect.  
 
3.2.5.2 Protocol 
 
 Cells were prepared for counting (Section 3.2.1.3). Serial dilutions were 
performed to obtain a final cell concentration as described above. Seeding of cells 
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with 2ml cell volume was performed in a 6-well plate, and incubated for 24 hours. 
Media was then replaced with 1ml fresh media, and supplemented with 1ml of X2 
drug dilution or control, with 3 wells per condition. Cisplatin 15µM was selected as a 
positive control. Plates were incubated for either 16 or 72 hours, according to 
experiment.  
 
 Cell cycle buffer was freshly prepared in a 15ml centrifuge tube. This 
consisted of 5ml sterile distilled water, 5µl 0.1M Sodium Chloride (final 
concentration 0.1mM), 50µl Triton X-100 (Sigma, T8787), and 50µl of 1mg/ml 
Propidium Iodide solution (Sigma, P4864). The Propidium Iodide allowed measure of 
DNA content within samples during analysis.  
 
 Following the required incubation period cells were then harvested. The 
media, from the 3 wells of each condition, were collated into a 15ml centrifuge tube 
and labelled. Cells were washed with 1ml PBS and 500µl TrypLE added to each well. 
Plates were incubated for 5-10 minutes until all cells had detached. The volume from 
3 wells was added to the corresponding 15ml tube. The tubes were then centrifuged at 
1,100 rpm for 4 minutes to obtain cell pellets, and the supernatant carefully discarded. 
Cell pellets were re-suspended using 500µl cell cycle buffer and the volume 
transferred to 5ml Culture Tubes (VWR, 60818-486). Samples were stored for 1-hour 
at 4oC and protected from light with aluminium foil.  
 
 Flow cytometry analysis was performed using the BD FACSCaliber (S/N 
E571) and BD Cell Quest software, which was kindly provided by Dr Farhat Khanim 
(University of Birmingham, West Midlands, UK). Samples were vortexed prior to 
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analysis, and were run to record 20,000 events per sample, and set to measure 
fluorescence using the FL2-H channel. This provided a histogram demonstrating 
phases of the cell cycle.  
 
Further analysis was performed using Flowing Software (Perttu Terho, 
University of Turku, version 2.5.1). This measured highlighted areas of a histogram, 
representing stages of the cell cycle as percentages (Figure 3.2). However, since the 
S-phase graphically overlaps into the G0/G1 and G2/M peaks these two phases are 
calculated by measuring one half of their peaks and multiplying by two. The S-phase 
was indirectly measured by subtracting measured values from 100 [S-phase (%) = 100 
– (% Sub G1) – (% >2N) – 2(% ½ G0/G1) – 2(% ½ G2/M)]. Experiments were 
repeated on three separate occasions to provide biological repeats, and averages 
calculated as percentages of cell cycle stages.   
 
 
Figure 3.2: Example flow cytometry histogram labelled with phases of cell cycle.  
1- Sub G1 area, 2- ½ G0/G1 area, 3- S-phase area (overlapping G0/G1 and G2/M 
areas), 4- ½ G2/M area, 5- >2N area 
 
 
1 2 3 4 5
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3.2.6 Clonogenic Assay 
 
3.2.6.1 Optimisation 
 
 The clongenic assay was utilised to assess the effect on colony formation with 
target drugs and controls. In principal, cells are seeded at densities low enough to 
allow single cells to emerge and incubated until adequate colonies have formed. 
Colonies are defined as individual cell clusters containing 50 or more cells (Rafehi et 
al., 2011, Franken et al., 2006). Initial optimisation and protocol was performed (Dr 
Rachel Watkins, InHANSE), and was adapted from a protocol by Franken et al 
(Franken et al., 2006). The ideal incubation period was determined to be between 10-
14 days.  
 
 Optimisation for seeding density was performed for SCC040, and required 
adjustments for further repeats, with three in total. Each drug or control required 
optimisation, and this required predicting the cell’s response to each treatment by 
analysing the effects seen in the other experiments and increasing or decreasing 
seeding density accordingly.  Differences in seeding densities were taken into account 
in the data analysis.  
 
 An initial clonogenic optimisation assay was performed for VU147, and 
included only untreated control, DMSO, Cisplatin 1µM and IR 1gy. However, the 
VU147 cells did not appear to form adequate colonies, and therefore no further 
repeats were attempted. Some cancer cell lines, including HNC cells, possess little or 
no clonogenicity, such as UM-SCC-29 (Tang et al., 2013).  
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3.2.6.2 Protocol 
 
 Cells were prepared for counting (Section 3.2.1.3). Serial dilutions were 
performed to obtain an initial stock cell concentration of 2,500-cells/ml. Using this 
stock, further dilutions were prepared to required volumes and cell densities. A 5ml 
volume was removed from tubes containing densities for planned irradiation. 
Irradiation therapy was performed at 1 Gy. In 6 well plates a 2ml cell volume of the 
three seeding densities was prepared, with 2 wells per density, and incubated for 24 
hours.  
 
Drug and control dilutions were then prepared to X2 concentration. Each plate 
was supplemented with 2ml/well of the required treatment to a final X1 concentration, 
and 2ml/well media added to the IR plate. Plates were incubated for a further 24 
hours. The media and drug/control were removed and then replaced with 4ml media 
per well.  Plates were incubated and monitored until colony formation (>50 
cells/colony) was visible in the untreated control (10-14 days).  
 
Staining of cells was performed using Crystal violet staining solution. Media 
was discarded, and wells washed with PBS solution. Crystal violet was added to cover 
the surface of each well. The staining solution was removed, and each plate was 
washed with tap water.  
 
Plates were scanned using the HP Scanjet 5590P. Images were analysed with 
Image J, and colonies counted by a pre-programmed Colony Counter macro kindly 
Chapter 3- Drug Re-purposing 
 
 111 
provided by Dr Peter Rae (InHANSE). Only one cell density was analysed for each 
condition, and was chosen according to their clonogenic appearance. Ideally the 
selected density resulted in neither under nor over confluent wells, with clearly 
demarcated colonies. Average values were calculated for the selected cell density. 
Calculations were then performed to determine plating efficiency for each condition, 
and surviving fractions as follows (Franken et al., 2006): 
 
Plating Efficiency % (PE) = (Number of colonies formed/Number of cells 
seeded) x 100 
 
Surviving Fraction % (SF) = (PE of treatment/PE control) x 100 
 
3.2.7 Statistical Analysis   
 
 Data were first analysed using Microsoft Excel for Mac 2011 (Version 
14.0.0). Statistical analysis was performed with the GraphPad software (Prism, 
Version 6). The proliferation assay data was assessed by two-way ANOVA and post-
hoc Tukey’s multiple comparisons test. The migration and clonogenic assays were 
analysed by one-way ANOVA and post-hoc Dunnett’s multiple comparisons test. The 
flow cytometry data was analysed by one-way ANOVA and post-hoc Tukey’s 
multiple comparisons test. The results of the post-hoc tests were reported, with 
adjusted p values. Statistical significance was considered at p<0.05.  
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3.3 Results 
 
3.3.1 Authentication of HPV status  
 
In order to authenticate the HPV status of the SCC040 and VU147 cell lines 
PCR testing was utilised. The HPV 16 E6 primer was expected to yield a PCR 
product of approximately 146bp. The result in Figure 3.3 confirms the HPV positive 
status of the VU147 cell line, yielding a PCR product between 100 to 200bp.  
 
 
Figure 3.3: PCR results of HPV 16 status. Lane 1=SCC040, Lane 2=VU147,  
Lane 3=Water only control, Lane 4=Positive control (previously tested VU147 
sample), Lane 5=Negative control (C33a sample). Fluorescence signal visible in 
lanes 2 and 4; corresponding between 100 to 200bp on the DNA ladder    
 
3.3.2 Proliferation assay 
 
3.3.2.1 SCC040 cell line  
 
 The initial HTS had identified several potential drug targets, and 3 candidates 
were selected and validated using the alamarBlue proliferation assay. The effect on 
proliferation with each drug and controls were compared to the untreated control 
1" 2" 3" 4" 5"
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(Figure 3.4). The statistically significant results are illustrated in Figure 3.5. INH001 
significantly reduced proliferation at 24 hours (64.4% +/- 3.5, p<0.01, N=3), 48 hours 
(69.9% +/- 11.5, p<0.001, N=3), and 72 hours (75.4% +/- 8.9, p<0.001, N=3). 
INH003 also demonstrated significant reduction at 24 hours (66.5% +/- 1.7, p<0.01, 
N=3), 48 hours (81.1% +/- 5.9, p<0.0001, N=3), and 72 hours (93.2% +/- 0.4, 
p<0.0001, N=3). However, INH002 and vehicle controls showed no significant effect 
on proliferation at these time points. The results of INH001 and INH002 were similar 
to the Cisplatin controls. Interestingly the Cisplatin controls did not significantly 
effect proliferation at 24 hours, but were more effective at 48 hours and 72 hours. For 
example, Cisplatin 5µM reduced proliferation by 40.3% (+/- 12.7, N=3) at 24 hours, 
72.7% (+/- 6.9, p<0.001, N=3) at 48 hours, and 82.7% (+/- 2.2, p<0.0001, N=3) at 72 
hours.  
 
Figure 3.4: Percentage proliferation of SCC040 cells with target drugs (solid lines), 
positive controls (dashed) and vehicle controls (dotted) at three time points, including 
standard error of means. Treatments were compared against untreated control (grey 
dashed line) 
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Figure 3.5: Treatments demonstrating statistically significant effects on SCC040 cells 
with percentage proliferation compared to untreated control, including standard 
error of means. Statistical analysis performed with two-way (time and treatment) 
ANOVA and Tukey’s post-hoc multiple comparisons test.  
 (N=3; **p<0.01, ***p<0.001, ****p<0.0001)       
 
3.3.2.2 VU147 cell line 
 
 The proliferation assay results for VU147 are demonstrated in Figure 3.6, and 
statistically significant outcomes in Figure 3.7. At 24 hours none of the treatments or 
controls had a significant effect on proliferation. INH003 showed statistically 
significant reduction in proliferation at 48 hours (65.2% +/- 8.1, p<0.05, N=3), and 72 
hours (85.9% +/- 1.7, p<0.001, N=3). This was similar to Cisplatin 15µM at 48 hours 
(69.4% +/- 3.4, p<0.05, N=3), and 72 hours (84.5% +/- 4.2, p<0.001, N=3). Neither 
INH001 nor INH002 demonstrated a significant effect on proliferation.  
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Figure 3.6: Percentage proliferation of VU147 cells with target drugs (solid lines), 
positive controls (dashed) and vehicle controls (dotted) at three time points, including 
standard error of means. Treatments were compared against untreated control (grey 
dashed line) 
 
 
 
Figure 3.7: Treatments demonstrating statistically significant effects on VU147 cells 
with percentage proliferation compared to untreated control, including standard 
error of means. Statistical analysis performed with two-way (time and treatment) 
ANOVA and Tukey’s post-hoc multiple comparisons test.   
(N=3; *p<0.05, **p<0.01, ***p<0.001)       
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3.3.3 Migration assay 
 
3.3.3.1 SCC040 cell line 
  
The migration assay was performed using the scratch wound method and 
included INH001 and INH002. This assay was utilised at an early stage in our 
experiments, prior to the inclusion of INH003 and Ethanol control. Representative 
images (Figure 3.8) were taken after creating the wounds and again at 24 hours (time 
point of wound closure for untreated control). Both INH001 and INH002 appeared to 
show no significant effect on wound closure, and were comparable to untreated and 
vehicle-only controls. Cisplatin controls did demonstrate significantly reduced wound 
closure rates compared to untreated control (Figure 3.9). Cisplatin 5µM reduced 
wound closure by 53.6% (+/- 27.9, N=3), Cisplatin 10µM by 72.8% (+/- 24.3, p<0.05, 
N=3), and Cisplatin 15µM by 82.3% (+/- 17.3, p<0.01, N=3).  
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Figure 3.8: Migration assay for SCC040 cells treated with drug targets, vehicle-only 
controls and Cisplatin controls. Representative images were taken at 0 hours and 24 
hours, and demonstrate complete wound closure for all conditions apart from 
Cisplatin controls 
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Figure 3.9: Percentage wound closure in SCC040 cells treated with drug targets and 
controls compared to untreated control, including standard error of means. Statistical 
analysis performed with one-way ANOVA and Dunnett’s post-hoc multiple 
comparisons test.  
(N=3; *p<0.05, **p<0.01)       
  
3.3.3.2 VU147 cell line 
 
 The optimisation experiment for VU147 did not achieve 100% confluence by 
48 hours using a range of seeding densities (50,000 to 300,000 cells/well). In 
comparison the SCC040 cells reached 100% confluence by 48 hours when seeded at 
250,000 cells/well (Figure 3.10). This was essential prior to creating a wound, in 
order to assess migration of cells into the wound only. Therefore the migration assay 
was not performed for VU147 cells.  
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Figure 3.10: Representative images of both cell lines seeded at 250,000 cells/well at 
48 hours incubation in a 12-well plate: A) SCC040 cells at 100% confluence,  
B) VU147 cells not 100% confluent 
 
3.3.4 Flow cytometry 
 
3.3.4.1 SCC040 16 hours 
 
 
Figure 3.11: Histograms representing flow cytometry analysis at 16 hours for 
SCC040 cells with treatments and controls. The y-axis represents cell count and the 
x-axis represents Propidium Iodide relative fluorescence intensity measured via the 
FL2-H channel. The phases of the cell cycle are gated in order to measure area under 
the graph as a percentage of overall events (numbered 1-5)  
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 Flow cytometry was performed using Propidium Iodide to measure DNA 
content in cells, which is proportional to fluorescent intensity. The data was converted 
into histograms (Figure 3.11) to represent stages of the cell cycle. At 16 hours 
treatment the SCC040 cells demonstrated no significant change in histogram shape 
between all the conditions. The histograms were gated to calculate the percentage 
total events for each stage of the cell cycle (Figure 3.12). There was no statistically 
significant difference between the drug targets and controls after analysing with one-
way ANOVA and post-hoc Tukey’s multiple comparisons test.  
 
 
Figure 3.12: Percentage total events for each stage of the cell cycle at 16 hours 
treatment for SCC040 cells 
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3.3.4.2 SCC040 72 hours 
 
 
Figure 3.13: Histograms representing flow cytometry analysis at 72 hours for 
SCC040 cells with treatments and controls. Both INH003 and Cisplatin control 
demonstrated a cytotoxic effect on the cells 
 
 At 72 hours treatment of SCC040 cells both INH003 and Cisplatin control 
killed the cells, as demonstrated by the loss of normal cell cycle appearance in the 
histograms and peak in the Sub G1 area (Figure 3.13). However, INH001 and 
INH002 appeared to show a normal cell cycle graph with no significant effect on the 
percentage total events in the stages of the cell cycle (Figure 3.14).  
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Figure 3.14: Percentage total events for each stage of the cell cycle at 72 hours 
treatment for SCC040 cells 
 
3.3.4.3 VU147 16 hours 
 
 At the 16 hours treatment the VU147 cells did not demonstrate any significant 
change in the cell cycle histograms with the drug targets or controls (Figure 3.15). 
Comparing the percentage of total events at each cell cycle stage, there was no 
statistically significant difference between the various conditions (Figure 3.16).  
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Figure 3.15: Histograms representing flow cytometry analysis at 16 hours for VU147 
cells with treatments and controls 
 
 
Figure 3.16: Percentage total events for each stage of the cell cycle at 16 hours 
treatment for VU147 cells 
 
 
 
Untreated( Water( DMSO(
Ethanol( INH001( INH002(
INH003( Cispla=n(15μM(
1 2 3 4 5
1.  Sub(G1(
2.  G0/G1(
3.  SFphase(
4.  G2/M(
5.  >2N(
FL2FH(
Ce
ll(
co
un
t(
300(
0(
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
To
ta
l E
ve
nt
s 
VU147 (16 hours) 
>2N 
G2/M 
S-phase 
G0/G1 
Sub G1 
Chapter 3- Drug Re-purposing 
 
 124 
3.3.4.4 VU147 72 hours 
 
 The cell cycle analysis for VU147 at 72 hours demonstrated no significant 
change in histograms between the drug targets and vehicle controls (Figure 3.17). 
Only Cisplatin 15µM control altered the appearance of the cell cycle histogram, with 
an increase percentage of Sub G1 and G2/M areas and reduction in G0/G1 peak 
(Figure 3.18). Comparing to untreated control Cisplatin showed a statistically 
significant difference in Sub G1 (p<0.0001), G0/G1 (p<0.0001), and G2/M (p<0.05).  
The Sub G1 area represents fragmented DNA and debris, and therefore apoptotic 
cells. The increase in G2/M peak and reduction in G0/G1 suggests arrest of cell cycle 
at the G2/M phase.  
 
Figure 3.17: Histograms representing flow cytometry analysis at 72 hours for VU147 
cells with treatments and controls. Only Cisplatin control appeared to alter the 
appearance of the cell cycle, with an increase in Sub G1 and G2/M areas, and a 
reduction in the G0/G1 peak 
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Figure 3.18: Percentage total events for each stage of the cell cycle at 72 hours 
treatment for VU147 cells 
 
 
3.3.5 Clonogenic assay 
 
3.3.5.1 SCC040 cell line 
 
 The clonogenic assay was utilised to further assess the effect of drug targets 
on proliferation and cell survival. The required cell seeding density for each condition 
was predicted from previous optimisation experiments and assays. Lower seeding 
densities indicated no or non-significant effect on colony formation. Therefore the 
untreated and vehicle-only controls, which have demonstrated no effect on previous 
assays, were seeded at lower densities. Similarly INH002 was found to have no 
significant effect on the clonogenic assay, even at lower seeding densities. In contrast 
INH001 and INH003 showed significant effects on the assay, and required higher 
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seeding densities. Even at 5000 cells/well there was no visible colony formation with 
INH002 (Figure 3.19).       
 
 
Figure 3.19: Representative wells of clonogenic assay with SCC040 cells treated with 
drug targets, vehicle controls and positive controls. Individual colonies represent 50 
or more cells per cluster. Cell seeding density is stated in brackets. INH001 showed 
no visible colony formation even at a higher cell seeding density of 5000 cell/well  
 
 Quantitative analysis was performed to calculate the percentage survival 
fraction of each condition compared to the untreated control (Figure 3.20). INH002 
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had a non-significant reduction in survival of 21.5% (+/- 6.0, N=3). INH001 
demonstrated a significant reduction of 99.5% in survival (+/- 0.5, p<0.0001, N=3), as 
did INH003 with 83% reduction (+/- 8.7, p<0.0001, N=3). These were similar to 
Cisplatin 1µM (82.6%, +/- 4.0, p<0.0001, N=3) and IR 1gy (75.9%, +/- 3.4, 
p<0.0001, N=3).  
 
 
Figure 3.20: Percentage survival fraction compared to untreated control of SCC040 
cells with drug targets and controls. INH001 and INH002 demonstrated significant 
reduction in survival fraction, comparable to Cisplatin and IR positive controls. 
Statistical analysis with one-way ANOVA and post-hoc Dunnett’s multiple 
comparisons test.  (N=3; ****p<0.0001)       
 
3.3.5.2 VU147 cell line 
  
 Optimisation of the clonogenic assay with VU147 cells did not demonstrate 
colony formation (Figure 3.21). Therefore further testing with drug targets was not 
performed.  
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Figure 3.21: Representative wells of untreated VU147 cells at 3 cell seeding 
densities. The cells did not appear to grow into colonies 
 
3.4 Discussion 
 
 The initial aim of this drug re-purposing study was to validate the results of 
the primary HTS of a drug library, which identified several potential drug targets 
including INH001, INH002 and INH003. Various assays were employed to 
investigate the effect of these drugs on cell proliferation, migration, cell cycle analysis 
and colony formation in clonogenic assays. This drug targets were tested separately 
on a HPV negative and a HPV positive cell line.  
 
 INH001 demonstrated a statistically significant anti-proliferative effect in 
SCC040 cells using the alamarBlue assay at all measured incubation time-points. This 
was similar to the effect of Cisplatin 5µM control. INH001 also significantly reduced 
clonogenicity and survival in the clonogenic assay with SCC040 cells, and was more 
effective than Cisplatin 1µM control. However, no significant effect was 
demonstrated with SCC040 cells in the migration and flow cytometry assays. 
Furthermore INH001 showed no effect on VU147 cells in the proliferation and flow 
cytometry experiments. Water was included as the vehicle-only control, and 
1000#cells# 1500#cells# 2000#cells#
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demonstrated no effect in any of the assays. Therefore it appears that while INH001 
exhibits anti-proliferative effect in both the alamarBlue and clonogenic assays, it did 
not demonstrate a significant effect in the flow cytometry assay compared to both 
INH003 and Cisplatin control. The varying seeding densities employed between these 
assays may partly explain this result. Both the proliferation and clonogenic 
experiments were seeded at lower cell densities (25,000 cells/ml and 2,500 cell/ml 
respectively) compared to the migration and flow cytometry assays (250,000 cells/ml 
and 50,000 cells/ml respectively). In fact INH001 showed the highest potency in the 
clonogenic assay, which was seeded at the lowest cell density of all the assays. 
Another aspect to consider is the effect of the drugs on the assays themselves. In the 
case of INH001 we experienced a change in colour of media (containing phenol red) 
from red to yellow on adding the drug during serial dilutions, indicating a more acidic 
solution. This is particularly important when utilising the alamarBlue reagent, which 
measures the conversion of Resazurin to Resorufin, which involves an oxidation-
reduction reaction. Therefore INH001 may have interacted with alamarBlue to 
provide a false positive result. However, the proliferation assay included a drug-only 
plate for each time-point, and further analysis revealed no significant effects with 
INH001 on the readings. Moreover the results were standardised by subtracting the 
drug-only readings. The different efficacy profile of INH001 between cell lines would 
also suggest a true effect. The clonogenic assay provided a qualitative and 
quantitative method of analysing the effect of the drugs on cell survival, and 
confirmed the results of INH001 from the proliferation assay. The INH001 drug 
belongs to the class of water-soluble vitamins, which are commonly found in fruit and 
vegetables. Historically fruits and vegetables have been advocated by the medical 
profession, and are thought to be beneficial for general health and disease prevention. 
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An early meta-analysis of epidemiological studies investigated the relationship 
between fruit and vegetable intake and risk of cancer (Block et al., 1992). The study 
found the relative risk of laryngeal cancer was more than 2-fold with low fruit and/or 
vegetable consumption, and also 2-fold increase risk with oral and pharyngeal 
cancers. The INHANCE study (Chuang et al., 2012) found an inverse relationship 
between risk of HNC and consumption of fruits and vegetables (odd ratios 0.52 and 
0.66 respectively). In another meta-analysis of oral cancer risk the authors found that 
consumption of fruit was associated with a 49% reduction in cancer risk, and 50% 
risk reduction with vegetable intake (Pavia et al., 2006). A recent meta-analysis found 
that for every increase portion of fruit and vegetables consumed per day significantly 
lowered all-cause mortality rate, with the maximum benefit derived from 5 portions 
daily (Wang et al., 2014). This supports the current 5-a-day campaign endorsed by 
various countries, including the United Kingdom, to encourage disease prevention.   
 
 In contrast to INH001 and INH003 the INH002 drug target appeared to have 
no significant effect on any of the assays, either with SCC040 or VU147 cells. 
Therefore it appears INH002 was a false positive result from the initial HTS. While 
HTS of drugs has the potential advantage of being less time consuming and resource-
intensive, there will undoubtedly be several false negative and false positive results. 
This can be attributed to the weakness inherent in any assay utilised, as well as the 
arbitrary incubation period and efficacy cut-off points used to define a potential drug 
target. For example, the alamarBlue assay result for INH002 at 24 hours indicated a 
reduced proliferation of 21.9% (+/- 9.0) in SCC040 cells. Therefore INH002 can be 
considered a target in HTS when using an efficacy cut-off point of 26-50% reduction 
in proliferation. Another aspect to consider is the effect of vehicle-only control on the 
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assays, which was DMSO in the case of INH002. This may also cause a false positive 
reading during HTS. However, DMSO control did not show any significant effect in 
any of the assays. Although our assays show INH002 to have no true effect on both 
cancer cell lines, previous studies have demonstrated several anti-hypertensive drugs 
with re-purposing potential. An Italian study found RND-Me, an α1-adrenergic 
receptor ligand, demonstrated anti-proliferative properties against a panel of cancer 
cell lines including HNC cells (Zagni et al., 2015). In another study 3 commercially 
available anti-hypertensive drugs (Lisinopril, Propranolol, Nifedipine) were tested in-
vitro against various cancer cell lines, and also tested on EACC (Ehrlich Ascites 
Carcinoma Cell) in an animal model (El Sharkawi et al., 2013). At 3000µg/ml 
concentration Propranolol reduced EACC growth by 97.7%, Lisinopril by 18.28%, 
and Nifedipine by 11.40%.  
 
 Among our 3 drug targets INH003 demonstrated the greatest effect across the 
assays and in both cell lines. INH003 showed a statistically significant anti-
proliferative effect on SCC040 cells at all measured time-points. In the VU147 cells 
the anti-proliferative effect was significant at 48 and 72 hours only. This result was 
similar to the Cisplatin 15µM control in both cell lines. The flow cytometry 
experiment in SCC040 cells at 72 hours found INH003 to exert a significant effect on 
cell cycle with a peak in Sub G1, which was similar to the Cisplatin control. 
However, this effect was not demonstrated in the flow cytometry assay of VU147 
cells at 16 and 72 hours. The clonogenic assay with SCC040 cells provided further 
evidence of INH003 potency, with a statistically significant reduction in colony 
formation similar to Cisplatin and IR controls. The vehicle-only control, Ethanol, 
showed no significant effect on any assay. These results validate the initial HTS, and 
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were more consistent across the assays compared to INH001. The effect of INH003 
appears more pronounced in the SCC040 cells compared to VU147 cells, and this will 
be discussed later. Previous studies have discussed the potential use of anti-helminthic 
drugs in cancer treatment. An interesting case report from Sweden described the 
treatment of a 74-year old male patient with refractory metastatic colon cancer 
(Nygren et al., 2014). The patient was initially treated with radical surgical resection 
and post-operative chemotherapy, but metastatic disease progression was observed. 
The authors had previously identified Mebendazole during in vitro drug re-purposing 
experiments using colon cancer cells. Thus the patient was consented for 
Mebendazole treatment, and after six weeks a repeat CT scan revealed almost 
complete disease remission. This case highlights the potential of drug re-purposing in 
a real clinical setting. Ideally cancer therapies should display high efficacy and 
selectivity, as do the anti-helminthic drugs. Elucidating a common pathway between 
cancers and parasitic infections may identify potential drug targets, and provide an 
insight into their mechanism of action.  
 
 Cisplatin was included as a positive control, which is the current standard 
chemotherapy treatment in HNC. We found a significant effect of Cisplatin on both 
cell lines, which was reproducible in all the assays. However, Cisplatin controls only 
demonstrated a significant effect on proliferation at 48 and 72 hours in both cell lines. 
In the migration assay the Cisplatin controls all showed an effect on wound closure, 
with Cisplatin 10µM and 15µM being statistically significant. There was no 
significant effect on the flow cytometry cell cycle analysis at 16 hours, but at 72 hours 
an abnormal cell cycle pattern was demonstrated in SCC040 cells and G2/M cell 
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cycle arrest in VU147 cells. The clonogenic assay also showed a statistically 
significant reduction in SCC040 cell colony formation with Cisplatin control.   
 
 Although only 2 assays (alamarBlue and flow cytometry) contained both cell 
lines for comparison, we found a difference in drug effect profiles between SCC040 
and VU147 cells. The SCC040 cells appeared to demonstrate more susceptibility to 
INH001 and INH003, as well as Cisplatin control.  While INH001 demonstrated a 
significant effect on proliferation of SCC040 cells, no effect was seen in VU147 cells. 
INH003 also demonstrated significant effect on SCC040 cell proliferation at all 
incubation time-points, but only at 48 and 72 hours in VU147 cells, albeit less 
pronounced. For example, at 72 hours with INH003 there was a 93.2% (p<0.0001) 
reduction in proliferation with SCC040 cells compared to 85.9% (p<0.001) with 
VU147 cells. INH003 exhibited a significant effect on SCC040 cells in the flow 
cytometry assay, but no measurable effect on VU147 cells. The Cisplatin control also 
demonstrated a variation between cell lines. For example, Cisplatin 5µM reduced 
SCC040 cell proliferation by 82.7% (p<0.0001) at 72 hours, but had a non-significant 
reduction of 61.2% in VU147 cells. Flow cytometry analysis at 72 hours showed a 
significant effect of Cisplatin in SCC040 cells, while VU147 cells demonstrated a less 
significant increase in Sub G1 area and G2/M peak. The varying results could be 
attributed to the HPV status of the chosen cell lines; SCC040 cells are HPV negative 
and VU147 cells HPV positive. The SCC040 cells also contain wild-type p53, 
whereas the HPV positivity of VU147 cells is likely to disrupt the p53 pathway 
(Figure 1.7). As previously discussed, p53 is known as a tumour suppressor gene 
product and has numerous cellular roles, including cell cycle arrest and senescence 
(Figure 3.22). Therefore the SCC040 cells containing functional p53 are likely to 
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respond to potential drug targets by inducing cell cycle arrest and/or apoptosis. 
However, the VU147 cells containing HPV oncoproteins would disrupt these 
pathways and encourage cellular immortalisation.  
 
Figure 3.22: p53 cellular pathways and functions (Brown et al., 2009) 
 
 There are several inherent limitations to our study that we have considered 
when designing the study and when interpreting the results of the current study. 
Firstly, initial identification of target drugs with HTS was defined by the effect of 
proliferation compared to untreated control. However, while proliferation is a key 
characteristic of cancer cells there are other pathological traits, such as invasion, 
metastasis and angiogenesis. These are known as the hallmarks of cancer (Hanahan et 
al., 2000). Therefore initial HTS defined by anti-proliferation effects is likely to 
exclude other potential targets with anti-cancer properties. However, without an 
automated and cost-effective alternative the cell viability assays are ideal for HTS. 
Furthermore any HTS tool will return a number of false positive and false negative 
results. In the case of false positive targets this can lead to ‘dead-ends’ during 
validation, which is particularly important with time and resource constraints. The 
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assay results of true positive targets can help refine the HTS and better predict which 
potential drug target will be successful. Another limitation was the selection of cell 
lines. The SCC040 cell line was ideal due to its’ commercial availability, HPV 
negative status and ability to grow successfully in vitro. In contrast the VU147 cell 
line was non-commercial and could not be optimised in the migration and clonogenic 
assays. Initially another HPV positive cell line (SCC154) was purchased but did not 
provide satisfactory growth results in cell culture. Optimisation of SCC154 cells or 
sourcing an alternative cell line would provide an ideal candidate to compare against 
the SCC040 cells. The various assays employed during this project will obviously 
have their own limitations. For example, the limits to the alamarBlue assay were 
discussed earlier. However, the optimisation of each assay prior to application of drug 
targets helped to ensure improved accuracy and reproducibility.  
 
 The results of our study have identified both INH001 and INH003 as potential 
drug targets and warrant further investigations. Additional assays could be utilised to 
elucidate the mechanism of action of these targets. For example, apoptosis can be 
measured with Caspase 3/7, Annexin V/ PI or TUNEL assays. An invasion assay may 
also help to elucidate the inhibitory effects of target compounds on cancer cell 
metastatic properties. Identifying more drug targets can be achieved by screening 
other drug libraries and on-going literature searches can be used to put together 
unique collections of drugs that exhibit promising activity in other types of cancers. 
The INHANSE group has already begun investigations into combination of drug 
compounds with standard treatments, such as Cisplatin and IR. These may yield even 
more potent treatment results in a potentially synergistic manner. Animal models and 
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experiments on primary cell culture are also underway, and the outcomes will enable 
progression into Phase 3 of the AcceleraTED project.  
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  Despite great advances in our understanding of disease pathogenesis and 
treatments cancer remains a significant burden, with profound effects on patient 
morbidity and mortality. An evolving principle is the concept of personalised and 
tailored management of cancer patients, in order to improve outcomes and prognostic 
accuracy. However, this requires a greater understanding of the relationship between 
tumour and patient characteristics, as well as improved treatment options. The main 
objectives of this thesis were to investigate the survival outcomes of oropharyngeal 
cancer (OPC) according to a combination of HPV and p16 status, and to evaluate the 
drug re-purposing potential of three drug targets (INH001, INH002, INH003) using 
HNC cells lines. Firstly, a systematic review and descriptive analysis was conducted 
to assess the prognostic significance of HPV/p16 in OPC, with particular interest in 
the importance of the discordant groups. Secondly, various laboratory assays were 
utilised to assess the effect of the three drug targets on HPV negative (SCC040) and 
HPV positive (VU147) cell lines.  
 
4.1 HPV+/p16+ has the best prognostic outcome and HPV-/p16- has 
the worst 
 
 Previous studies and meta-analysis have confirmed that HPV positive OPC 
show significantly better prognostic outcomes compared to HPV negative tumours 
(Ragin et al., 2007b, Dayyani et al., 2010, O'Rorke et al., 2012). The results of this 
systematic review corroborate these findings. Combining HPV and p16 status, the 
best prognostic group was HPV+/p16+ (true positive). Both at 3 and 5-year time 
points the HPV+/p16+ cohort had the most favourable DFS, DSS and OS rates 
compared to the other HPV/p16 groups. Furthermore HPV+/p16+ conferred the 
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lowest HR values of all the groups. In contrast the HPV-/p16- cohort had the lowest 3 
and 5-year DFS, DSS and OS rates, as well as the least favourable HR values.  
 
 There were differences in demographics and characteristics between these two 
groups. Although both cohorts had a greater proportion of male subjects, the 
HPV+/p16+ displayed even more male preponderance. The HPV+/p16+ also showed 
a lower average mean age compared to HPV-/p16-. The HPV-/p16- cohort contained 
a greater proportion of smokers and excessive drinkers. However, the HPV+/p16+ 
group comprised a larger percentage of grade IV tumours, and was more likely to be 
poorly differentiated cancers. The HPV+/p16+ group was also more associated with 
tonsil or base of tongue tumours.  
 
 The findings of this review support the notion that HPV-driven cancers are 
likely to represent a different disease entity, with unique pathophysiology and tumour 
characteristics (Psyrri et al., 2011). Previous authors have utilised HPV status for 
prognostic modelling (Ang et al., 2010). While true positive and true negative 
tumours represent the vast majority of cases, the discordant groups were the main 
focus of this review.   
 
4.2 HPV-/p16+ has a better prognostic outcome compared to 
HPV+/p16- 
 
 Previous studies have shown that the discordant groups, HPV+/p16- and 
HPV-/p16+, represent a minority of cases (see Table 1.1). This review confirms these 
findings, with both discordant groups representing 20% of the total cases. This 
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proportion was more that the example studies represented in Table 1.1. Comparing 
between the discordant groups the HPV-/p16+ showed more favourable 3 and 5-year 
DFS and OS rates. Furthermore the HPV-/p16+ demonstrated lower HR values 
compared to the HPV+/p16- group, albeit with limited data availability.  
 
 There were also differences between group characteristics. The HPV-/p16+ 
cohort demonstrated a lower average mean age and a greater male percentage 
compared to the HPV+/p16- group. Both groups demonstrated similar proportion of 
smokers, but the data for alcohol consumption was unavailable for HPV-/p16+. All 
the HPV-/p16+ cases were either tonsil or base of tongue, whereas the HPV+/p16- 
contained a higher proportion of other oropharyngeal sites. Finally, the HPV-/p16+ 
cohort showed a higher percentage of stage IV tumours compared to HPV+/p16-.  
 
 It appeared that the HPV-/p16+ cohort had similar group characteristics 
compared to the true positive cohort, whereas the HPV+/p16- group correlated with 
the true negative cohort. Prognostically, while the true positive group demonstrated 
the best survival outcomes the next best survival rates were seen in the HPV-/p16+ 
cohort. Therefore it would appear from this systematic review that HPV-/p16+ status 
confers a better prognostic outcome compared to the HPV+/p16- discordant group. 
However, statistical significance could not be determined due to the limited data 
available.  
 
 The significant bias in the review results relates to the differences between 
HPV and p16 testing among the included studies. Ideally this would have been 
explored further if a meta-analysis were possible, by use of sensitivity analysis. 
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Therefore while the descriptive analysis has provided an insight into the differences 
between the HPV/p16 subgroups the results remain inconclusive.   
 
4.3 INH001 and INH003 show promising drug re-purposing potential 
 
 Three drug targets were chosen for further analysis in this study following the 
initial high-throughput screening. The results confirmed the potential of INH001 and 
INH003 as drug re-purposing agents. INH001 showed a statistically significant effect 
on both the proliferation and clonogenic assays using the SCC040 (HPV negative) 
cell line. In comparison there was no significant effect with INH001 using the VU147 
(HPV positive) cell line. However, INH003 demonstrated a statistically significant 
effect on the proliferation assay using both these cell lines. Furthermore INH003 
showed a statistically significant effect on both the flow cytometry and clonogenic 
assays using the SCC040 cell line. In contrast INH002 was found to have no 
significant effect across all the assays and cell lines.  
 
 Based on the data of this study both INH001 and INH003 would be ideal 
targets to continue further testing as part of the AcceleraTED project (Figure 3.1). In 
fact, the results of the assays have shown INH003 to be at least as effective on the two 
cell lines compared to Cisplatin, which is the current standard chemotherapy agent. 
These results are both exciting and promising for future cancer therapy, and has 
demonstrated the potential of the AcceleraTED project to deliver novel cancer 
treatments. There are many other drug targets to be tested, and numerous HNC cell 
lines to be utilised. Furthermore this system, if successful, can be easily adapted to 
discover therapies in other cancers. Ideally these would deliver new and effective 
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treatments, which could be both beneficial for patient outcomes and financially 
attractive.  
  
4.4 Target drugs more effective in the HPV negative (SCC040) cell 
line 
 
 The results of the assays demonstrated a difference in drug target effect 
between the cell lines. While INH001 and INH003 significantly effected proliferation 
in the SCC040 cell line, only INH003 had a significant effect on the VU147 cell line. 
However, the effect of INH003 was not as pronounced using the VU147 cell line. 
Furthermore the Cisplatin control also showed less effect on VU147 cells, albeit still 
statistically significant. This would suggest the VU147 cells were more resistant to 
these agents. The role of HPV in disease pathogenesis and cellular mechanisms with 
regards to the results is unclear. Further testing with other HPV positive and negative 
cell lines would be required to investigate this. However, one major difficulty 
encountered with the VU147 cells was in optimisation for the assays. The migration 
and clonogenic assays could not be applied to the VU147 cells due to the results of 
the optimisation experiments. Understandably some cells lines do not exhibit the 
characteristics required for in-vitro testing. Again, testing with other HPV positive 
cell lines may provide further results.  
 
4.5 Implications for personalised treatment and prognosis 
 
 As research into cancer mechanisms and therapies continues to expand the key 
component of success is in translational research. The vast majority of basic science 
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discoveries rarely impact on real life patients. For example, only 1 in 5000 new drug 
discoveries are eventually marketed (MedicineNet, 1999). In order to improve the 
success and effectiveness of research greater emphasis on personalised therapy is 
required. Just as we are individuals, the course of any disease is unique between 
people, with patient-related factors and disease-related factors interacting. Treatments 
based on ‘one-size fits all’ are likely to be less effective.      
 
 The results of systematic review and drug re-purposing study demonstrate the 
potential to focus on personalised management. Biomarkers, genetic studies and risk 
factors of disease can help predict the risk of specific cancers and prognostic 
outcomes. Furthermore both patient and disease-related characteristics can be 
combined to predict the most effective treatment strategy. The future model of cancer 
management would involve an individual and tailored approach. For example, 
patients would initially attend a specialist clinic where numerous blood tests, imaging 
and tissue sample extractions are performed. Tissue samples would undergo 
laboratory testing, including molecular and genetic profiling. A panel of biomarkers 
would also be tested. The results of all these tests can then be integrated into a 
prognostic model, which can predict survival and potential therapeutic response 
(Figure 4.1). Furthermore, patients will have tailored therapy based on the 
AcceleraTED model of testing, involving primary cell cultures and mouse models. 
Target drugs and combination therapies will be selected for the patient, and response 
to treatment monitored by the multidisciplinary team (i.e. clinician, radiologist, 
pathologist, scientist etc.). Combining effective drug targets, radiotherapy and surgery 
would provide the best prognostic outcomes, with improved patient quality of life. 
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Depending on the prognostic models patients would either undergo aggressive 
treatment, or de-escalation therapy in order to ensure the best outcomes.   
 
 
Figure 4.1: Example of the stages for personalised cancer therapy  
(MD-Anderson, 2015) 
 
4.6 Future studies  
 
 The systematic review of OPC has provided an interesting insight into the 
prognostic potential of combining HPV and p16. The results could be improved by 
the addition of high quality RCTs, if possible, in future reviews. Additionally a 
consensus on HPV and p16 testing is required to improve the accuracy of the data and 
minimise bias. Given the current data available an IPA (individual patient analysis) 
can be performed with the studies included in this review, and also include studies 
excluded from the systematic review due to lack of data. This is considered the ‘gold-
standard’ for systematic reviews, and should also enable a meta-analysis.  
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 Further studies on the impact of HPV in OPC are required. In particular the 
exact pathogenesis of HPV-driven cancer in head and neck sites needs to be 
elucidated. Epidemiological studies are on going, and the future trend of OPC 
incidence would be particularly interesting given the changing demographics and 
disease characteristics. The impact on HPV vaccination employed in several countries 
also merits further studies.  
 
 The work on the AcceleraTED project is on going with the InHANSE group. 
The results of the drug screening and validation assays will be further tested in mouse 
models and primary cell cultures. The imminent opening of ITM (Institute of 
Translational Medicine) in Birmingham will help to propel this and many projects, 
and ultimately improve patient outcomes.  
 
 The future prospects for cancer patients certainly appear to be positive, with 
many exciting new discoveries and innovations. While curing cancer may never be 
possible, each breakthrough brings us closer to that reality.   
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